



CONGRES ASH 2017

Participation IUCT Oncopole - CRCT

55 présentations posters dont

- 3 communications orales
- 6 en premier auteur



INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE
Oncopole



3 Communications orales

398 – Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Program: Oral and Poster Abstracts

Type: Oral

Session: 731. Clinical Autologous Transplantation: Results: Novel Conditioning & Maintenance Approaches

Sunday, December 10, 2017: 9:45 AM

Bldg C, Lvl 1, C101 Aud (Georgia World Congress Center)

Murielle Roussel¹, Benjamin Hebraud, MD¹, Valerie Lauwers-Cances, MD², Margaret Macro, MD³, Xavier Leleu, MD, PhD⁴, Cyrille Hulin, MD⁵, Lionel Karlin, MD⁶, Bruno Royer, MD⁷, Aurore Perrot, MD⁸, Philippe Moreau⁹, Denis Caillot, MD¹⁰, Sophie Rigaudeau, MD¹¹, Mamoun Dib, MD¹², Emmanuelle Nicolas-Virelizier, MD¹³, Martine Escoffre-Barbe, MD¹⁴, Karim Belhadj, MD¹⁵, Brigitte Pegourie, MD¹⁶, Anne-Marie Stoppa, MD¹⁷, Carla Araujo, MD¹⁸, Chantal Doyen, MD¹⁹, Jean Fontan, MD²⁰, Brigitte Kolb, MD²¹, Laurent Garderet, MD, PhD²², Sabine Brechignac, MD²³, Jean Valere Malfuson, MD²⁴, Veronique Dorvaux, MD²⁵, Pascal Lenain, MD²⁶, Omar Benbrahim, MD²⁷, Arnaud Jaccard²⁸, Cecile Borel, MD¹, Herve Avet Loiseau, MD, PhD²⁹ and Michel Attal, MD, PhD³⁰

¹Hematology Department, IUCT-Oncopole, Toulouse, France

²USMR, service d'Epidemiologie, CHU Toulouse, TOULOUSE, France

³Haematology Department, Caen University Hospital, Caen, France

⁴Hematology, Department of Oncology-Haematology and Cell Therapy, CHU, Poitiers, INSERM, Inserm CIC 1402, Poitiers, France, Poitiers, France

⁵Hopital Haut leveque CHU, bordeaux, France

⁶Ch Lyon Sud, Pierre Bénite, France

⁷Department of Hematology, University Hospital, Amiens, France

⁸Hôpitaux De Brabois, Vandoeuvre Les Nancy, France

⁹Clinical Hematology, Nantes University Hospital, Nantes, France

¹⁰Department of Hematology, University Hospital of Dijon, Dijon, France

¹¹Service Hematologie, CHU Andre Mignot, Versailles, France

¹²Hématologie - CHU - Hôpital du Bocage, Angers, France

¹³Onco-hematology, Centre Leon Berard, University Claude Bernard Lyon 1, Lyon, France

¹⁴Hematology, University Hospital CHU Rennes, Rennes, France

¹⁵CHU Henri Mondor, Creteil, France

¹⁶Hôpital A.Michallon, CHU Grenoble, Grenoble, France

¹⁷Institut J Paoli-Calmettes, Marseille, France

¹⁸Centre Hospitalier de la côte basque, Bayonne, France

¹⁹Cliniques Universitaires UCL Mont-Godinne, Yvoir, BEL

²⁰Service Hematologie, Hôpital Jean Minjot, Besancon, France

²¹Hopital Robert Debre, Reims Cedex, France

²²Service d'Hématologie et Thérapie Cellulaire, Hopital Saint Antoine, Paris, France

²³Hématologie, HOPITAL AVICENNE, Bobigny, France

²⁴Hôpital d'instruction des armées Percy, Paris Cedex 10, FRA

²⁵Medecine Interne, Hopital Notre Dame de Bon Secours, Metz-Thionville, France

²⁶Hematology department, Centre Henri Becquerel, Rouen, France

²⁷Hopital La Source–CHR Orléans, Service d'Hématologie, Orleans, FRA

²⁸Hematologie clinique, Limoges, FRA

²⁹IUCT ONCOPOLE, Toulouse, FRA

³⁰IUCT–Oncopole, Toulouse, France

508 – A Prospective Phase II of Daratumumab in Previously–Treated Systemic Light–Chain (AL) Amyloidosis

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy in Myeloma and Amyloid

Sunday, December 10, 2017: 5:15 PM

Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)

Murielle Roussel^{1*}, Anne–Marie Stoppa, MD², Aurore Perrot, MD^{3*}, Lionel Karlin, MD^{4*}, Bertrand Arnulf, MD, PhD^{5*}, Margaret Macro, MD^{6*}, **Antoine Huart, MD^{7*}**, Laurent Frenzel, MD, PhD^{8*}, Pierre Morel, MD^{9*}, Eileen Boyle, MD^{10*}, Veronique Dorvaux, MD^{11*}, Giampaolo Merlini, MD¹², Giovanni Palladini, MD, PhD¹³, David Lavergne, PhD^{14*}, Frank Bridoux, MD, PhD^{15*} and Arnaud Jaccard^{14*}

¹Hematology Department, IUCT–Oncopole, Toulouse, France

²Institut J Paoli–Calmettes, Marseille, France

³Hôpitaux De Brabois, Vandoeuvre Les Nancy, France

⁴Ch Lyon Sud, Pierre Bénite, France

⁵Département d'Immuno–Hématologie, APHP, Paris, France

⁶Haematology Department, Caen University Hospital, Caen, France

⁷Department of Nephrology, Oncopole, Toulouse, France

⁸Hematology Department / Hemophilia Center, INSERM U1163, CNRS ERL 8254, Paris, France

⁹Department of Hematology, Chu Amiens, Salouel, FRA

¹⁰Department of Hematology, CHU, Lille, FRA

¹¹Medecine Interne, Hopital Notre Dame de Bon Secours, Metz–Thionville, France

¹²Foundation IRCCS Policlinico San Matteo, University of Pavia, Italy, Pavia, ITA

¹³Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

¹⁴Department of Hematology and National Referral Center for AL Amyloidosis, CHU Limoges, Limoges, France

¹⁵Department of Nephrology and National Referral Center for AL Amyloidosis, CHU, Poitiers, France

435 – Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance

Sunday, December 10, 2017: 12:30 PM

Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)

Hervé Avet-Loiseau, MD, PhD^{1*}, Valerie Lauwers-Cances, MD^{2*}, **Jill Corre, PharmD, PhD^{3*}**, Philippe Moreau^{4*}, Michel Attal, MD, PhD⁵ and Nikhil Munshi, MD⁶

¹IUC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

²USMR, service d'Epidemiologie, CHU Toulouse, TOULOUSE, France

³Unit for Genomics in Myeloma, Institut Universitaire du Cancer, Toulouse, FRA

⁴CHU de Nantes, Nantes, France

⁵IUCT-Oncopole, Toulouse, France

⁶J. Lipper Cancer Center for Multiple Myeloma, Dana Farber Cancer Institute, Boston, MA

6 posters en premier auteur

1041 – Risk Factors for Bleeding, Including Platelet Count Threshold, in Newly Diagnosed ITP Patients

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Marie Piel-Julian^{1}, Matthieu Mahévas^{2*}, Johanne Germain^{3*}, Laetitia Languille^{2*}, Thibault Comont^{4*}, Natacha Brun^{5*}, Claire Dingremont^{6*}, Brice Castel^{7*}, Sophie Arista^{8*}, Serge Madaule^{9*}, Laurent Prudhomme^{10*}, Laurent Sailler^{1*}, Maryse Lapeyre–Mestre^{1*}, Nicolas Limal^{2*}, Odile Beyne–Rauzy^{1*}, Marc Michel^{12*}, Daniel Adoue^{13*}, Bertrand Godeau^{2*} and Guillaume Moulis, MD^{3,14,15*}*

¹Toulouse University Hospital, Toulouse, France

²CHU Henri Mondor, Créteil, France

³CIC 1436, Toulouse, France

⁴Toulouse–oncopole, Toulouse, FRA

⁵CH Rodez, Rodez, France

⁶Tarbes hospital, Tarbes, France

⁷Lourdes hospital, Lourdes, France

⁸Auch hospital, Auch, France

⁹Albi hospital, Albi, France

¹⁰Castres–Mazamet hospital, Castres, France

¹¹IUCT, Toulouse, France

¹²Henri Mondor Hospital, Assistance Publique Hopitaux de Paris, Paris XII universi, Creteil, FRA

¹³CHU de Toulouse, Toulouse Cedex 9, FRA

¹⁴CHU de Toulouse, Toulouse, France

¹⁵UMR 1027 INSERM–University of Toulouse, Toulouse, France

2990 – Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Loïc Ysebaert, MD, PhD^{1*}, Sarah Cadot, PhD^{2*}, Salim Kanoun, MD^{3*}, Soleakhena Ken^{3*}, Christian Recher, MD, PhD⁴, François Malgouyres⁵, Sébastien Gadat⁶, Loïc Dupre, PhD^{7*} and Anne Quillet Mary, PhD^{2*}

¹Service d'Hématologie, IUCT–Oncopole, Toulouse, France

²CRCT, Inserm UMR 1037, Toulouse, France

³Radiology Department, IUC Toulouse Oncopole, Toulouse, France

⁴Clinical Hematology, IUCT Oncopole, Toulouse University Hospital, Toulouse, France

⁵CNRS UMR 5219, Institut des Mathématiques de Toulouse, Toulouse, France

⁶Université Toulouse I Capitole, Toulouse School of Economics, Toulouse, France

⁷CPTP, Inserm UMR 1043, Toulouse, France

1731 – Immune Recovery Refines the Prognostic Impact of Minimal Residual Disease on Overall and Progression Free Survivals after Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in CLL Patients

Program: Oral and Poster Abstracts

Session: 642. CLL: Therapy, excluding Transplantation: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Martin Gauthier^{1*}, Florence Durrieu^{2*}, Michael Peres, MD^{3*}, Elodie Martin, MSc^{4*}, Thomas Filleron, PhD^{5*}, Christian Recher, MD, PhD⁶, Anne Quillet Mary, PhD^{7*} and Loïc Ysebaert, MD, PhD^{8*}

¹Hematology Department, IUC Toulouse Oncopole, Toulouse, France

²Hematology Department, Institut Bergonié, Bordeaux, France

³Laboratoire d'Hématologie, Institut Universitaire du Cancer Toulouse – Oncopole, Toulouse, France

⁴Biostatistics unit, IUC Toulouse Oncopole, Toulouse, France

⁵Biostatistics unit, Institut universitaire du cancer Toulouse– Oncopole, Toulouse, France

⁶Clinical Hematology, IUCT Oncopole, Toulouse University Hospital, Toulouse, France

⁷CRCT, Inserm UMR 1037, Toulouse, France

⁸Service d'Hématologie, IUCT–Oncopole, Toulouse, France

3903 – Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10⁹/L?

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Sarah Bertoli, MD, PhD¹, Suzanne Tavitian, MD², Françoise Huguet, MD², Muriel Picard, MD³, François Vergez, DVM, PhD⁴, Eric Delabesse, MD, PhD⁴, Audrey Sarry², Emilie Berard, MD⁵ and Christian Recher, MD, PhD²

¹Hematology Department, Institut Universitaire du Cancer de Toulouse, Toulouse, France

²Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

³Critical care Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

⁴Hematology Laboratory, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

⁵Epidemiology Department, Toulouse University Hospital, Toulouse, France

1711– International, Practice–Based Recommendations for Prediction of Bleedings and Anti–Platelet/Anti–Coagulant (AP/AC) Co–Medications in CLL Patients Taking Ibrutinib

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Evgeny Nikitin, MD¹, Jennifer Series², Aleksandr Poletaev³, Mikhail Panteleev, PhD, Dr.Sc, Prof.⁴, Georg Hopfinger, MD⁵, Vadim Ptushkin, MD^{6,7}, Ulrich Jaeger, MD⁸, Bernard Payrastre, PhD² and Loïc Ysebaert, MD, PhD²

¹Hematology Research Center of Russia, Moscow, Russia

²CHU Rangueil, Laboratoire d'Hémostase, Toulouse, France

³National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Molecular hemostasis laboratory, Moscow, Russian Federation

⁴National Scientific and Practical Center of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Molecular hemostasis laboratory, Moscow, France

⁵Department of Internal Medicine I, Vienna General Hospital, Vienna, Austria

⁶FGBU FNKC DGOI MZSR RF, Moscow, RUS

⁷S.P.Botkin hospital, Outpatient department for hematology oncology and chemotherapy, Moscow, Russian Federation

⁸Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive

Cancer Center, Medical University of Vienna, Medical University of Vienna, Vienna, Austria

²Service d'Hématologie, IUCT-Oncopole, Toulouse, France

1040 – Prevalence of Cardiovascular Risk Factors and Incidence of Venous and Arterial Thrombosis in Non-Splenectomized Immune Thrombocytopenia Adult Patients in Sweden and France. Results from Two Nationwide Studies

Program: Oral and Poster Abstracts

Session: 311. Disorders of Platelet Number or Function: Poster I

Saturday, December 9, 2017, 5:30 PM-7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

*Charlotta Ekstrand¹, Bérangère Baricault², Marie Linder³, Margaux Lafaurie², Laurent Sailler⁴, Maryse Lapeyre-Mestre⁴, Helle Kieler¹, Shahram Bahmanyar¹ and **Guillaume Moulis, MD^{2,5}***

¹Karolinska Institutet, Stockholm, Sweden

²UMR 1027 INSERM-University of Toulouse, Toulouse, France

³Karolinska Institutet, Stockholm, France

⁴Toulouse University Hospital, Toulouse, France

⁵CIC 1436, Toulouse, France

46 participations posters

190 – Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Novel Agents and Upfront Approaches

Saturday, December 9, 2017: 2:45 PM

Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center)

Rene-Olivier Casasnovas, MD¹, Gilles Andre Salles, MD, PhD², **Lucie Oberic, MD³***, Caroline Bodet-Milin⁴*, Josette Briere, MD⁵*, Franck Morschhauser, MD, PhD⁶*, Herve Tilly⁷, Vincent Ribrag, MD⁸, Thierry Lamy, Pr, MD, PhD⁹, Catherine Thieblemont, MD, PhD¹⁰, Herve Maisonneuve, MD¹¹*, Remy Gressin,*

MD^{1,2}, Krimo Bouabdallah, MD^{1,3*}, Corinne Haioun^{1,4}, Gandhi Damaj, MD^{1,5}, Luc Mathieu Fornecker^{1,6*}, Reda Bouabdallah, MD^{1,7*}, Pierre Feugier, MD^{1,8*}, Richard Delarue, MD^{1,9}, Anna Schmitt^{2,10*}, Christophe Bonnet, MD, PhD^{2,11*}, Guillaume Cartron, MD, PhD^{2,12*}, Jean-Philippe Jais, MD, PhD^{2,13*}, Alina Berriolo-Riedinger, MD^{2,14*}, Thierry Jo Molina, MD, PhD^{2,15*}, Emmanuel Itti, MD, PhD^{2,16*} and Steven Le Gouill, MD, PhD^{2,17*}

¹Hematology, University Hospital, Dijon, France

²Hematology, Hospices Civils de Lyon – Université de Lyon, Pierre-Bénite, France

³IUCT–Oncopole, Department of Hematology, Toulouse, France

⁴Nuclear Medicine department, University hospital, Nantes, France

⁵Pathology, Hopital Saint-Louis, France, France

⁶Hematology, Université de Lille, EA GRIIOT, Lille, France

⁷Hematology Department, Centre Henri Becquerel, Rouen, France

⁸Hematology, Institut Gustave Roussy, Villejuif, France

⁹Hematology, Hospital Pontchaillou, Rennes, France

¹⁰Hematology, CHU Paris–GH St-Louis Lariboisiere F. Widal–Hopital, Saint Louis, Paris, FRA

¹¹Oncology and Hematology Department, CH, La Roche-sur-Yon, France

¹²Hematology, CHU Grenoble, Grenoble, France

¹³Haematology, CHU de Bordeaux, Bordeaux, France

¹⁴Lymphoid malignancies unit, University Hospital Henri Mondor, Creteil, France

¹⁵Service d'Hématologie, CHU Caen, Caen, France

¹⁶Haematology, University Hospital, Strasbourg, France

¹⁷Institut Paoli Calmettes, Department of Hematology, Marseille, France

¹⁸Hematology Department, CHU Nancy, Vandoeuvre Les Nancy Cedex, France

¹⁹Hematology Department / Hemophilia Center, Necker University Hospital, AP-HP, Paris, France

²⁰Institut Bergonie, Bordeaux, France

²¹Clinical Hematology, CHU University of Liège, Liège, BEL

²²Department of Clinical Hematology, University Hospital of Montpellier, Montpellier, France

²³Hopital Necker, Department of Biostatistics, Paris, France

²⁴Nuclear Medicine Department, Centre G.F. Leclerc, Dijon, France

²⁵Department of Pathology, Necker University Hospital, Paris, FRA

²⁶Nuclear Medicine, UPEC University, CRETEIL, France

²⁷Department of Hematology, Nantes University Hospital, Nantes, France

313 – "Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia – Results from the EURO-SKI Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 632. Chronic Myeloid Leukemia: Therapy: Treatment Discontinuation, Dose Reduction, and Prognostic Indicators

Sunday, December 10, 2017: 7:30 AM

Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)

Susanne Saussele, MD¹, Johan Richter, MD, PhD^{2*}, Joelle Guilhot, PhD³, Henrik Hjorth-Hansen, MD⁴, Antonio Medina de Almeida, MD, PhD^{5*}, Jeroen J. W. M. Janssen, MD^{6*}, Jiri Mayer, MD⁷, Perttu Koskenvesa, MD^{8*}, Panayiotis Panayiotidis, MD, PhD^{9*}, Ulla Olsson-Strömberg, MD, PhD^{10*}, Juan Luis Steegmann, MD, PhD¹¹, Hanne Vestergaard, MD^{12*}, Hans Ehrencrona, MD, PhD^{13*}, Veli Kairisto^{14*}, Kateřina Machová Poláková, PhD^{15*}, Martin Müller, MD^{16*}, Satu Mustjoki, MD, PhD^{8,17}, Marc G. Berger, MD, PhD^{18*}, Philippe Rousselot, MD^{19,20,21*}, Martine Escoffre-Barbe, MD^{22*}, Gabriel Etienne, MD, PhD^{23*}, Jolanta Dengler, MD^{24*}, **Françoise Rigal-Huguet**, MD^{25*}, Nikolas von Bubnoff, MD^{26*}, Hana Klamova, MD^{15*}, Edgar Faber, MD^{27*}, François Guilhot, MD^{3*}, Kourosh Lotfi, MD^{28*}, Delphine Rea, MD²⁹, Tim H. Brummendorf, MD³⁰, Gorgine de Greef, MD^{31*}, Leif Stenke, MD^{32,33*}, Franck Emmanuel Nicolini, MD, PhD^{34,35,36}, Laurence Legros, MD, PhD^{37*}, Andreas Burchert, MD³⁸, Jaroslava Voglová, MD^{39*}, Aude Charbonnier, MD^{40*}, Emmanuel Gyan, MD-PhD⁴¹, Maria-Elisabeth Goebeler, MD^{42*}, Peter E. Westerweel, MD^{43*}, Andreas Hochhaus, MD⁴⁴, Markus Pfirrmann^{45*} and Francois-Xavier Mahon, MD, PhD⁴⁶

¹Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany

²Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden

³INSERM CIC 1402, CHU de Poitiers, Poitiers, France

⁴Department of Hematology, St Olavs Hospital, Trondheim, Norway

⁵Instituto Portugues de Oncologia de Lisboa de Francisco Gentil, Lisbon, Portugal

⁶Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

⁷Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic

⁸Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Comprehensive Cancer Center, Helsinki, Finland

⁹Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece

¹⁰Department of Hematology, University Hospital Uppsala, Uppsala, Sweden

¹¹Servicio de Hematología y Grupo 44 IIS-IP, Hospital Universitario de la Princesa, Madrid, Spain

¹²Department of Hematology, Odense University Hospital, Odense, Denmark

¹³Department of Clinical Genetics, Skåne University Hospital, Lund, Sweden

¹⁴Department of Clinical Chemistry, Turku University Central Hospital, Turku, Finland

¹⁵Institute of Hematology and Blood Transfusion, Prague, Czech Republic

¹⁶Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany

¹⁷Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland

¹⁸Hématologie Biologique and EA 7453 CHELTER, CHU Estaing and Université Clermont Auvergne, Clermont-Ferrand, France

- ¹⁹Department of Hematology and Oncology, Centre Hospitalier de Versailles, INSERM UMR 1173, Université Versailles Saint-Quentin-en-Yvelines, Université Paris Saclay, Le Chesnay, France
- ²⁰Hôpital de Versailles, Le Chesnay, France
- ²¹Fi-LMC group, Pessac, France
- ²²Service d'Hématologie Adulte, CHU de Rennes, Rennes, France
- ²³Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Bordeaux, France
- ²⁴Onkologische Schwerpunktpraxis Heilbronn, Heilbronn, Germany
- ²⁵Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France
- ²⁶Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation, Universitätsklinikum Freiburg, Freiburg, Germany
- ²⁷Department of Hemato-Oncology, Palacký University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Czech Republic
- ²⁸Department of Hematology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
- ²⁹Service d'Hématologie adulte et Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France
- ³⁰Uniklinik RWTH Aachen, Aachen, Germany
- ³¹Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands
- ³²Division of Hematology, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden
- ³³Division of Hematology, Department of Medicine, Karolinska Institute, Stockholm, Sweden
- ³⁴Hématologie Clinique, Centre Léon Bérard, Lyon, France
- ³⁵Hématologie clinique 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France
- ³⁶INSERM U1052, Centre de recherche en cancérologie de Lyon (CRCL), Lyon, France
- ³⁷Hematology department, Centre Hospitalier Universitaire de Nice, Nice, France
- ³⁸Klinik für Innere Medizin, Schwerpunkt Hämatologie, Onkologie und Immunologie, Universitätsklinikum Marburg, Marburg, Germany
- ³⁹4th Department of Internal Medicine – Hematology, Charles University, Faculty Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
- ⁴⁰Paoli-Calmettes Institute, Marseille, France
- ⁴¹Hématologie et Thérapie Cellulaire, CHU de Tours, Tours, France
- ⁴²Medizinische Klinik und Poliklinik, Universitätsklinikum Würzburg, Würzburg, Germany
- ⁴³Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
- ⁴⁴Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
- ⁴⁵Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany
- ⁴⁶Bergonié Cancer Institute INSERM Unit 916, University of Bordeaux, Bordeaux, France
-

1722 – A Retrospective Analysis of 450 *TP53* Mutations in a Real Life Cohort of CLL from the French Innovative Leukemia Organization (FILO) Group

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Fanny Baran–Marszak, MD, PhD^{1*}, Valerie Vidal^{2*}, Myriam Hormi^{3*}, Virginie Eclache^{4*}, Lauren Veronese, MD, PhD^{5*}, Olivier Tournilhac, MD, PhD^{6*}, Frederic Davi^{7*}, Florence Nguyen–Khac, MD, PhD^{8*}, Veronique Leblond⁹, **Eric Delabesse, MD, PhD^{10*}**, **Loic Ysebaert, MD, PhD^{11*}**, Audrey Bidet, PharmD^{12*}, Marie–Sarah Dilhuydy, MD^{13*}, Stephanie Poulain, MD, PhD^{14*}, Charles Herbaux^{15*}, Marie–Helene Estienne, PharmD^{16*}, Caroline Dartigeas^{17*}, Cedric Pastoret, MD^{18*}, Sophie de Guibert^{19*}, Stephane Giraudier, MD, PhD^{20*}, Jehan Dupuis, MD^{21*}, Pascale Cornillet–Lefebvre^{22*}, Anne Quinquenel^{23*}, Sophy Laibe^{24*}, Thérèse Aurran, MD^{25*}, Dina Naguib, MD, MASTERS^{26*}, Xavier Troussard, MD²⁷, Pierre Sujobert, MD, PhD^{28*}, Anne–Sophie Michallet, MD, PhD^{29*}, Catherine Thieblemont, MD, PhD^{30*}, Remi Letestu^{31*}, Gregory Lazarian, PharmD^{32*}, Vincent Levy, MD, PhD^{33*}, Thierry Soussi^{34*}, Sophie Raynaud, MD, PhD^{35*} and Florence Cymbalista, MD³⁶

¹Laboratoire d'hematologie, Hopital Avicenne, Bobigny, France

²Service d'hematologie, Hopital Avicenne, Bobigny, France

³Laboratoire d'Hematologie, Hopital Avicenne, Bobigny, France

⁴Hopital Avicenne, APHP, Université Paris 13, Bobigny, FRA

⁵University Hospital of Clermont–Ferrand, Cytogenetic Laboratory, Clermont–Ferrand, France

⁶Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite Clermont Auvergne, EA7453 CHELTER, CIC501, Clermont Ferrand, France

⁷Hopital Pitie–Salpetriere and University Pierre et Marie Curie, Paris, France

⁸Hopital Pitie–Salpetriere, UPMC Paris 6, INSERM U1138, Paris, France

⁹AP–HP Hôpital Pitié–Salpêtrière, Paris, France

¹⁰Hematology Laboratory, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

¹¹Service d'Hematologie, IUCT–Oncopole, Toulouse, France

¹²Hématologie Biologique, CHU Bordeaux, Bordeaux, France

¹³CHU Hopitaux de Bordeaux, Pessac, France

¹⁴Service d'Hématologie Cellulaire, Centre de Biologie et Pathologie, CHRU de Lille, France/ INSERM UMR–S 1172, IRCL, Lille, FRA

¹⁵Service des Maladies du Sang, CHRU de Lille, Lille, France

¹⁶Laboratoire d'Hematologie, Hopital Bretonneau, Tours, France

¹⁷Hôpital Bretonneau CHU de Tours, Tours, France

¹⁸Laboratoire d'Hematologie, CHU de Rennes, RENNES, FRA

¹⁹Centre Hospitalier Pontchaillou, Rennes, FRA

²⁰APHP Hopital Mondor, Créteil, FRA

- ²¹Lymphoid malignancies unit, Henri Mondor Hospital, Creteil, France
- ²²Laboratory of Hematology, Centre Hospitalier Universitaire de Reims, Reims, France
- ²³Hôpital Robert Debré, Reims Cedex, FRA
- ²⁴Cytogénétique et Génétique Moléculaire, Institut Paoli-Calmettes, Marseille, France
- ²⁵Institut Paoli Calmette, Marseille, France
- ²⁶Laboratoire d'Hématologie, CHU Caen, CAEN, France
- ²⁷Department of Haematology, C.H.U. de Caen, Caen Cedex9, France
- ²⁸CHU de Lyon, Pierre Bénite, FRA
- ²⁹CHU Lyon, LYON, France
- ³⁰Hematology Department, Hospital Saint-Louis, Paris, France
- ³¹Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, FRA
- ³²Dana-Farber Cancer Institute, Boston, MA
- ³³URC/CRC, Hopital Avicenne, AP-HP, Bobigny, France
- ³⁴Department of Oncology-Pathology, Karolinska Institutet; UPMC; INSERM, U1138, Stockholm, Sweden
- ³⁵CHU of Nice, Onco-hematology Laboratory, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France
- ³⁶Laboratoire d'hématologie, Hôpital Avicenne, Paris, France

889 – Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Therapies for Elderly Patients with AML

Monday, December 11, 2017: 6:15 PM

Bldg B, Lvl 5, Murphy BR 1-2 (Georgia World Congress Center)

Norbert Vey¹, Pierre-Yves Dumas, MD^{2*}, **Christian Recher**, MD, PhD³, Lauris Gastaud, MD^{4*}, Bruno Lioure, MD^{5*}, Claude-Eric Bulabois, MD^{6*}, Cecile Pautas^{7*}, Jean-Pierre Marolleau, MD, PhD⁸, Stéphane Leprêtre, MD^{9,10*}, Emmanuel Raffoux, MD^{11*}, Xavier Thomas, MD¹², Yosr Hicheri^{13*}, Caroline Bonmati, MD^{14*}, Bruno Quesnel, MD, PhD¹⁵, Philippe Rousselot, MD^{16,17,18*}, Sylvie Castaigne, MD, PhD¹⁹, Eric Jourdan, MD^{20*}, Jean Valère Malfuson^{21*}, Gaele Guillerme, MD^{22*}, Jean Henri Bouhris^{23*}, Mario Ojeda, MD^{24*}, Mathilde Hunault, MD, PhD^{25*}, Norbert Ifrah, MD, PhD²⁶, Claude Gardin, MD, PhD^{27*}, Andre Delannoy, MD²⁸, Lucile Beautier^{29*}, Carine Paturel, PhD^{30*}, Pascale Andre, PhD²⁹, Robert Zerbib^{31*}, Claude Preudhomme, PharmD, PhD³², Antoine Toubert, MD, PhD^{33*}, Nicolas Dulphy, PhD^{34*}, Daniel Olive, MD, PhD³⁵, Arnaud Pigneux, MD^{36*} and Herve Dombret, MD³⁷

- ¹Clinical Hematology, Paoli-Calmettes Institute, Marseille, France
- ²Clinical Hematology, Bordeaux University Hospital, Pessac, France
- ³Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole – CHU de Toulouse, Toulouse, France
- ⁴Hematology, Centre Antoine Lacassagne, Nice, France
- ⁵Hematology and Oncology, Hopital Hautepierre, Strasbourg, France
- ⁶Hematology, CHU Grenoble, Grenoble, France
- ⁷Hematology, Henri Mondor Hospital, Creteil, France
- ⁸Hematology Department, Amiens University Hospital, Amiens, France
- ⁹Department of clinical Hematology, Centre Henri Becquerel, Rouen, France
- ¹⁰CLCC H Becquerel, Rouen, France
- ¹¹Hematology Department, Saint-Louis Hospital, Paris, France
- ¹²Centre Hospitalier Lyon Sud, HCL, Pierre Bénite, France
- ¹³Hematology, Montpellier University Hospital, Montpellier, France
- ¹⁴Clinical Hematology, Nancy University Hospital, Vandoeuvre Lès Nancy, France
- ¹⁵Hôpital Claude-Huriez – CHRU Lille, Lille, France
- ¹⁶Hematology department, CH de Versailles, Le Chesnay, France
- ¹⁷Hôpital de Versailles, Le Chesnay, France
- ¹⁸Department of Hematology and Oncology, Centre Hospitalier de Versailles, INSERM UMR 1173, Université Versailles Saint-Quentin-en-Yvelines, Université Paris Saclay, Le Chesnay, France
- ¹⁹Hematology, CH Versailles, Le Chesnay, France
- ²⁰Clinical Hematology, Nimes University Hospital, Nîmes, France
- ²¹Dept. of Hematology, Hopital Percy, Clamart, France
- ²²Hematology and Oncology, CHU Brest, Brest, France
- ²³Stem Cell Transplantation, Institut Gustave Roussy, Villejuif, France
- ²⁴Clinical Hematology, Mulhouse Hospital, Mulhouse, France
- ²⁵Angers University, Angers, France
- ²⁶Hematology Department, Centre Hospitalier Angers, Angers, France
- ²⁷Hematology, Hopital Avicenne, Bobigny, France
- ²⁸Hopital de Jolimont, Haine Saint Paul, Belgium
- ²⁹Innate Pharma, Marseille, France
- ³⁰R&D, Innate Pharma, Marseille, France
- ³¹Innate Pharma, MARSEILLE, France
- ³²Centre de Biologie-Pathologie, Centre Hospitalier Universitaire de Lille, Lille, France
- ³³INSERM UMR 1160, Hopital Saint-Louis – APHP, Paris, France
- ³⁴Service d'Immunologie et Histocompatibilité / UMRS-1160 INSERM Institut Universitaire d'Hématologie,, Hopital Saint-Louis, Paris, France
- ³⁵Tumor Immunology Lab., INSERM UMR 891, Marseille, France

³⁶Hôpital Haut Lévêque–CHU de Bordeaux, Pessac Cedex, France

³⁷Hematology, Hopital Saint Louis, Paris, France

652 – Efficacy of Chemotherapy or Chemo–Anti–PD–1 Combination after Unsatisfactory Response of Anti–PD–1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma Immunotherapy Studies; nodular lymphocyte predominant Hodgkin lymphoma clinical studies

Monday, December 11, 2017: 11:15 AM

Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)

Cédric Rossi, MD^{1,2*}, Julia Gilhodes^{3*}, Marie Maerevoet, MD^{4*}, Charles Herbaux^{5*}, Pauline Brice, MD⁶, Sylvain Garciaz^{7*}, Cecile Borel, MD^{8*}, Loic Ysebaert, MD, PhD^{9*}, Lucie Oberic, MD^{10*}, Julien Lazarovici, MD^{11*}, Bénédicte Deau–Fisher, MD^{12*}, Jehan Dupuis, MD^{13*}, Adrien Chauchet^{14*}, Julie Abraham, MD^{15*}, Fontanet Bijou^{16*}, Aspasia Stamatoullas–Bastard^{17*}, Jean Valère Malfuson^{18*}, Camille Golfier^{1*}, Camille Laurent, MD, PhD^{3*}, Salim Kanoun, MD^{3*}, Thomas Filleron, PhD^{19*}, Rene–Olivier Casasnovas, MD^{20*} and Hervé Ghesquières, MD, PhD^{21*}

¹Hospital, Dijon, France

²Hospital, TOULOUSE, France

³Institut universitaire du cancer Toulouse– Oncopole, Toulouse, France

⁴Hospital Jules Bordet, Bruxelles, France

⁵Service des Maladies du Sang, CHRU de Lille, Lille, France

⁶Hematology Department, AP–HP Hopital Saint–Louis, Paris, France

⁷Institut Paoli Calmettes, Department of Hematology, Marseille, France

⁸Hematology Department, IUCT–Oncopole, Toulouse, France

⁹Departement d'Hematologie, IUCT–Oncopole, Toulouse, France

¹⁰IUCT–Oncopole, Department of Hematology, Toulouse, France

¹¹Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France

¹²Cochin Hospital, Hematology Department, Paris, France

¹³Hospital intercommunal, Créteil, France

¹⁴Hospital, Besancon, France

¹⁵Hospital, Limoges, France

¹⁶Hospital Bergonié, Bordeaux, France

¹⁷Hospital Henri Becquerel, Rouen, France

¹⁸Hôpital Percy, Clamart, France

¹⁹Biostatistics unit, Institut universitaire du cancer Toulouse– Oncopole, Toulouse, France

²⁰CHU Dijon, Dijon, FRA

²¹Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon–Sud, Lyon, France

497– Phase II, Multicenter Trial, Exploring “Chemo–Sparing” Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Icll–07 Filo Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 642. CLL: Therapy, excluding Transplantation: Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments

Sunday, December 10, 2017: 5:30 PM

Bldg B, Lvl 5, Murphy BR 3–4 (Georgia World Congress Center)

Anne–Sophie Michallet, MD, PhD^{1*}, Marie–Sarah Dilhuydy, MD^{2*}, Fabien Subtil^{3*}, Valérie Rouille^{4*}, Beatrice Mahe, MD^{5*}, Kamel Laribi^{6*}, Bruno Villemagne^{7*}, Gilles Andre Salles, MD, PhD⁸, Olivier Tournilhac, MD, PhD^{9*}, Alain Jacques Delmer, MD¹⁰, Christelle Portois^{11*}, Brigitte Pegourie, MD^{12*}, Veronique Leblond^{13,14}, Cecile Tomowiak, MD^{15*}, Sophie de Guibert^{16*}, Frederique Orsini^{17*}, Anne Banos, MD^{18*}, Philippe Carassou^{19*}, Guillaume Cartron, MD, PhD^{20*}, Luc Mathieu Fornecker^{21*}, Loïc Ysebaert, MD, PhD^{22*}, Caroline Dartigeas^{23*}, Margot Truchan^{24*}, Thérèse Aurran, MD^{25*}, Florence Cymbalista, MD²⁶, Stéphane Leprêtre, MD^{27*}, Vincent Levy, MD, PhD^{28*}, Florence Nguyen Khac^{29*}, Magali Le Garff–Tavernier^{30*}, Carmen Aanaei^{31*}, Michel Ticchioni^{32*}, Remi Letestu^{33*} and Pierre Feugier, MD^{34*}

¹Centre Léon Bérard, LYON, FRA

²CHU Hopitaux de Bordeaux, Pessac, France

³Department of biostatistics, Hospices Civils de Lyon, LYON, France

⁴CHU, Montpellier, France

⁵Clinical Hematology, Nantes University Hospital, Nantes, France

⁶Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France

⁷CH La Roche sur Yon, La Roche Sur Yon, FRA

⁸Hematology, Hospices Civils de Lyon – Université de Lyon, Pierre–Bénite, France

⁹Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU, Université Clermont Auvergne, EA7453 CHELTER, CIC501, Clermont Ferrand, France

¹⁰Hematology department, Hopital Robert Debre CHU de Reims, Reims, FRA

¹¹hematology, CHU Saint Etienne, Saint Etienne, France

¹²Hôpital A.Michallon, CHU Grenoble, Grenoble, France

¹³Département d’Hématologie, Hôpital Pitié–Salpêtrière APHP, UPMC Université Paris, Paris, France

- ¹⁴Department of Clinical Hematology, AP-HP Hôpital Pitié-Salpêtrière, Paris, France
- ¹⁵Department of Oncology-Haematology and Cell Therapy, CHU, Poitiers, INSERM, Inserm CIC 1402, Poitiers, France, Poitiers, France
- ¹⁶Centre Hospitalier Pontchaillou, Rennes, FRA
- ¹⁷CH Annecy, ANNECY, France
- ¹⁸Clinical Hematology, Centre Hospitalier de la Cote Basque, Bayonne, France
- ¹⁹CH Metz, Metz, FRA
- ²⁰Department of Clinical Hematology, University Hospital of Montpellier, Montpellier, France
- ²¹Haematology, University Hospital, Strasbourg, France
- ²²Departement d'Hematologie, IUCT-Oncopole, Toulouse, France
- ²³Hôpital Bretonneau CHU de Tours, Tours, France
- ²⁴CHU Angers, ANGERS, France
- ²⁵Institut Paoli Calmette, Marseille, France
- ²⁶Laboratoire d'hématologie, Hôpital Avicenne, Paris, France
- ²⁷Department of clinical Hematology, Centre Henri Becquerel, Rouen, France
- ²⁸URC/CRC, Hopital Avicenne, AP-HP, Bobigny, France
- ²⁹APHP Hôpital de La pitié Salpêtrière, Paris Cedex 13, FRA
- ³⁰APHP Hôpital de la Pitié Salpêtrière, PARIS, France
- ³¹CHU Saint Etienne, Saint Etienne, France
- ³²CHU NICE, NICE, France
- ³³Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, FRA
- ³⁴Hematology Department, CHU Nancy, Vandoeuvre Les Nancy Cedex, France

899 – Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 632. Chronic Myeloid Leukemia: Therapy: Results of Clinical Trials

Monday, December 11, 2017: 7:15 PM

Bldg C, Lvl 2, C202-C204 (Georgia World Congress Center)

Franck Emmanuel Nicolini, MD, PhD^{1,2,3}, Gabriel Etienne, MD, PhD^{1,4*}, **Francoise Huguet, MD^{1,5*}**, Agnes Guerci-Bresler^{1,6*}, Aude Charbonnier, MD^{1,7*}, Martine Escoffre-Barbe, MD^{1,8*}, Viviane Dubruille, MD^{1,9*}, Hyacinthe Johnson-Ansah, MD^{1,10*}, Laurence Legros, MD, PhD^{1,11*}, Valerie Coiteux, MD^{1,12*}, Pascale Cony-Makhoul, MD, PhD^{1,13*}, Pascal Lenain, MD^{1,14*}, Lydia Roy, MD^{1,15*}, Philippe Rouselot, MD^{1,16,17*}, Denis Guyotat^{1,18*}, Jean-Christophe Ianotto, MD^{1,19*}, Martine Gardembas, MD^{1,20*}, Fabrice Larosa, MD^{1,21*}, Denis Caillot, MD^{1,22*}, Pascal Turlure, MD^{1,23*}, Stephane Courby, MD^{1,24*}, Philippe Quittet, MD^{1,25}, Eric Hermet, MD^{1,26*}, Shanti Ame, MD^{27,28*}, Simona Lapusan, MD^{1,29*}, Verane Schwartz,

PharmD^{30*}, Stephane Morisset, Stat^{31*}, Madeleine Etienne, CRA^{1,32*}, Delphine Rea, MD, PhD^{1,33*},
Stephanie Dulucq, PhD^{34,35*} and Francois-Xavier Mahon, MD, PhD^{1,36}

¹Fi-LMC group, Pessac, France

²Département d'Hématologie, Centre Leon Berard, Lyon, France

³Hematology department 1 G, Centre Hospitalier Lyon Sud, Pierre Benite, France

⁴Hematology Department, Institut Bergonie, Bordeaux, France

⁵Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

⁶Hematology department, CHU Brabois, Nancy, France

⁷Hematology department, Institut Paoli Calmettes, Marseille, France

⁸Hematology department, CHU Rennes, Rennes, France

⁹Clinical Hematology, Nantes University Hospital, Nantes, France

¹⁰Hematology department, CHU Caen, Caen, France

¹¹Hematology department, Hopital Archet, Nice, France

¹²Hematology department, CHU de Lille, Lille, France

¹³Centre Hospitalier Annecy-Genevois, Pringy, France

¹⁴Hematology department, Centre Henri Becquerel, Rouen, France

¹⁵Hematology department, Hopital Henri Mondor, Creteil, France

¹⁶Hematology department, CH de Versailles, Le Chesnay, France

¹⁷Hôpital de Versailles, Le Chesnay, France

¹⁸Hematology department, Institut de Cancerologie Lucien Neuwirth, Saint-Priest-en-Jarez, France

¹⁹Centre Hospitalier Universitaire, Brest, France

²⁰Hematology department, University Hospital Angers, Angers, France

²¹Hematology department, CHU Jean Minjoz, Besancon, France

²²Department of Hematology, University Hospital of Dijon, Dijon, France

²³Hematology department, Hopital Dupuytren, Limoges, France

²⁴Hematology department, CHU Grenoble, Grenoble, France

²⁵Hematology department, CHU Saint Eloi Montpellier, Montpellier, France

²⁶university hospital of Clermont-Ferrand, Unit of adult cell therapy and clinical hematology, Clermont-Ferrand, France

²⁷Hematology department, Hopital Civil , CHU Strasbourg, Strasbourg, France

²⁸Fi-LMC Group, Pessac, France

²⁹APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France

³⁰Pharmacy, Centre Hospitalier Lyon Sud, Pierre Benite, France

³¹Hematology department, Centre Leon Berard, Lyon, France

³²Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France

³³Hematology department, Hopital Saint Louis, Paris, France

³⁴Laboratory of Hematology, Hopital Haut Leveque, Pessac, France

³⁵Molecular Biology Laboratory, Hôpital Haut Lévêque, Pessac, France

³⁶Hematology Laboratory, Bordeaux University, Bordeaux Hospital, INSERM 1035, BORDEAUX, France

1003 – Coinfection with HCV or HBV Increases the Risk of Lymphoma in HIV-Positive Patients: A Combined Analysis of the Lymphovir-ANRS-CO16 and Fhdh-ANRS-CO4 Cohorts

Program: Oral and Poster Abstracts

Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Caroline Besson, MD, PhD^{1,2}, Nicolas Noel^{3*}, Remi Lancar^{4*}, Sophie Prevot^{5*}, Michele Algarte-Genin^{4*}, Rosenthal Eric^{6*}, Fabrice Bonnet^{7*}, Marie-Caroline Meyohas^{8*}, Marialuisa Partisan^{9*}, **Lucie Oberic, MD^{10*}**, Jean Gabarre^{11*}, Cecile Goujard^{12*}, Antoine Cheret^{13*}, Cedric Arvieux^{14*}, Bertrand Coiffier, MD, PhD¹⁵, Christine Katlama^{16*}, Dominique Salmon^{17*}, Francois Boue, MD, PhD^{18*}, Regis T. Costello, MD¹⁹, Nawel Mekerri^{4*}, Houria Hendel-Chavez^{20*}, Yassine Taoufik^{12*}, Helene Fontaine^{21*}, Paul Coppo, MD, PhD^{22*}, Nicolas Mounier^{23*}, Pierre Delobel^{24*} and Dominique Costagliola^{4*}

¹Inserm U1018, Centre pour la Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France

²CH Versailles, Le Chesnay, France

³APHP, Le Kremlin-Bicetre, France

⁴UPMC, Paris, France

⁵APHP, Clamart, France

⁶CHU Nice, Nice, France

⁷CHU Bordeaux, Bordeaux, France

⁸CHU Saint-Antoine, Paris, France

⁹CHU Strasbourg, Strasbourg, France

¹⁰IUCT-Oncopole, Department of Hematology, Toulouse, France

¹¹Hopital Pitie-salpetriere, Paris, France

¹²CHU Bicetre, Le Kremlin Bicetre, France

¹³CH Tourcoing, Tourcoing, France

¹⁴CHU Rennes, Rennes, France

¹⁵Department of Hematology, Hospices Civils de Lyon, Lyon, France

¹⁶CHU Pitie, Paris, France

¹⁷CHU Cochin, Paris, France

¹⁸Hopital Antoine Beclere, Clamart, FRA

¹⁹Hopital La Conception, Marseille, FRA

²⁰CHU Bicetre, Le Kremlin-Bicetre, France

²¹APHP, Paris, France

²²Saint-Antoine Hospital, Paris, France

²³CHU De Nice, Hôpital De L Archet, Nice, FRA

²⁴CHU Toulouse, Toulouse, France

2587 Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

Program: Oral and Poster Abstracts

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Maria Pilar Gallego Hernanz^{1*}, Marie C Bene, PharmSciD, PhD^{2*}, Pierre-Yves Dumas, MD^{3*}, Jacques Delaunay, MD^{4*}, Caroline Bonmati, MD^{5*}, Romain Guieze, MD, PhD^{6*}, Isabelle Luquet, MD^{7*}, Pascale Cornillet-Lefebvre^{8*}, **Eric Delabesse, MD, PhD^{7*}**, Jean-Christophe Ianotto, MD^{9*}, Mario Ojeda, MD^{10*}, Mathilde Hunault, MD, PhD^{11*}, Anne Banos, MD^{12*}, Bruno Lioure, MD^{13*}, Marc Bernard, MD^{14*}, Eric Jourdan, MD^{15*}, Norbert Vey¹⁶, Hacene Zerazhi^{17*}, Yosr Hicheri^{18*}, Ariane C Mineur^{19*}, Roselyne Delepine^{20*}, Jean Yves Cahn, MD, PhD^{21*}, Norbert Ifrah, MD²², **Christian Recher, MD, PhD²³** and Arnaud Pigneux, MD, PhD^{3*}

¹Clinical Hematology, Poitiers University Hospital, Poitiers, France

²Hematology Biology, Nantes University Hospital, Nantes, France

³Clinical Hematology, Bordeaux University Hospital, Pessac, France

⁴Clinical Hematology, Centre Catherine de Sienne, Nantes, France

⁵Clinical Hematology, Nancy University Hospital, Vandoeuvre Lès Nancy, France

⁶Clinical Hematology, University Hospital of Clermont-Ferrand, Unit of adult cell therapy and clinical hematology, Clermont Ferrand, France

⁷Hematology Biology, IUCT Oncopole Toulouse University Hospital, Toulouse, France

⁸Hematology Biology, Reims University Hospital, Reims, France

⁹Clinical Hematology, Institut de Cancéro-Hématologie, Brest University Hospital, Brest, France

¹⁰Clinical Hematology, Mulhouse Hospital, Mulhouse, France

¹¹CHU, Angers, France

¹²Clinical Hematology, Centre Hospitalier de la Cote Basque, Bayonne, France

¹³Clinical Hematology, Strasbourg University Hospital, Strasbourg, France

¹⁴Clinical Hematology, Rennes University Hospital, Rennes, France

¹⁵Clinical Hematology, Nimes University Hospital, Nîmes, France

¹⁶Clinical Hematology, Paoli-Calmettes Institute, Marseille, France

¹⁷Clinical Hematology, Avignon Hospital, Avignon, France

¹⁸Clinical Hematology, Montpellier University Hospital, Montpellier, France

¹⁹Bordeaux University Hospital, Pessac, France

²⁰Tours University Hospital, Tours, France

²¹Clinical Hematology, Grenoble University Hospital, Grenoble, France

²²Clinical Hematology, Angers University Hospital, Angers, France

²³Clinical Hematology, IUCT Oncopole, Toulouse University Hospital, Toulouse, France

4285 – Dynamic of Telomeric Parameters in Relapsing or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), an Analysis of the Filo ICLL001 Bomp Trial

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Laura Bounaix^{1*}, Andrei Tchirkov, MD, PhD^{2,3*}, Florence Nguyen-Khac, MD, PhD^{4*}, Patricia Combes^{5*}, Pierre Feugier, MD^{6*}, Laurence Sanhes^{7*}, Marie-Sarah Dilhuydy, MD^{8*}, Hussam Saad, MD^{9*}, **Loïc Ysebaert, MD, PhD**^{10*}, Choquet Sylvain^{11*}, Jean-Pierre Vilque^{12*}, Annie Brion^{13*}, Carla Araujo, MD^{14*}, Emmanuelle Ferrant^{15*}, Brigitte Dreyfus^{16*}, Alain Jacques Delmer, MD^{17*}, Malgorzata Truchan-Graczyk^{18*}, Stéphane Leprêtre, MD^{19*}, Sophie de Guibert^{20*}, Romain Guieze, MD, PhD^{21,22*}, Lauren Veronese, MD, PhD^{2,3*}, Richard Lemal, MD^{23*}, Philippe Vago^{24*}, Jacques-Olivier Bay, MD, PhD^{22,25*}, Marc G. Berger, MD, PhD^{26*}, Anna Schuh, MD, PhD^{27*}, Christophe Ferrand, PhD^{28*}, Roselyne Delepine^{29*}, Véronique Leblond³⁰ and Olivier Tournilhac, MD, PhD^{31*}

¹Department of Hematology and Cellular Therapy, CHU Estaing, Clermont Ferrand, France

²University of Auvergne, INSERM UMR 1240, Clermont-Ferrand, France

³University Hospital of Clermont-Ferrand, Cytogenetic Laboratory, Clermont-Ferrand, France

⁴Hopital Pitié-Salpêtrière, Paris, France, France

⁵Service cytogénétique, CHU Estaing, Clermont-Ferrand, France, Clermont-Ferrand, France

⁶Hematology Department, CHU Nancy, Vandoeuvre Les Nancy Cedex, France

⁷CH, Perpignan, France

⁸CHU Hopitaux de Bordeaux, Pessac, France

⁹CHU, Brest, FRA

¹⁰Service d'Hématologie, IUCT-Oncopole, Toulouse, France

¹¹Département d'Hématologie, Hôpital de la Pitié Salpêtrière, Paris, France

¹²CHU Caen, Caen, France

¹³Hôpital Jean Minjoz, Besancon Cedex, FRA

¹⁴Centre Hospitalier de la Cote Basque, Bayonne, France

¹⁵CHU de Dijon, Dijon, France

¹⁶hématologie clinique, CHU Poitiers, Poitiers, France

¹⁷Hematology department, Hopital Robert Debre CHU de Reims, Reims, FRA

¹⁸CH Saumur, Saumur, France

¹⁹Department of clinical Hematology, Centre Henri Becquerel, Rouen, France

²⁰Centre Hospitalier Pontchaillou, Rennes, FRA

²¹Clinical Hematology, University Hospital of Clermont–Ferrand, Unit of adult cell therapy and clinical hematology, Clermont Ferrand, France

²²University of Auvergne, EA7453, CIC501, Clermont–Ferrand, France

²³university hospital of Clermont–Ferrand, Unit of adult cell therapy and clinical hematology, Clermont Ferrand, France

²⁴Department of Medical Cytogenetics, University Hospital, Clermont–Ferrand, France

²⁵Department of Hematology, Clermont–Ferrand University Hospital, Clermont–Ferrand, France

²⁶Service d'Hématologie Biologique and EA 7453 CHELTER, CHU Estaing and Université Clermont Auvergne, Clermont–Ferrand, France

²⁷Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

²⁸INSERM UMR 1098. Université de Bourgogne Franche Comté, Besancon, France

²⁹Tours University Hospital, Tours, France

³⁰AP–HP Hôpital Pitié–Salpêtrière, Paris, France

³¹Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU, Université Clermont Auvergne, EA7453 CHELTER, CIC501, Clermont Ferrand, France

837 – A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma: Therapy, excluding Transplantation: Studies in Relapsed and Refractory Multiple Myeloma

Monday, December 11, 2017: 5:00 PM

Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)

Laurent Garderet, MD, PhD¹, Frederique Kuhnowski, MD^{2*}, Jean Yves Mary, MD^{3*}, **Murielle Rousel^{4*}**, Martine Escoffre–Barbe, MD^{5*}, Ingrid Lafon, MD^{6*}, Thierry Facon, MD^{7*}, Lionel Karlin, MD^{8*}, Aurore Perrot, MD^{9*}, Philippe Moreau^{10*}, Gerald Marit, MD^{11*}, Anne–Marie Stoppa, MD¹², Jean–Pierre Marolleau, MD, PhD¹³, Carine Chaletteix, MD^{14*}, Mourad Tiab^{15*}, Carla Araujo, MD^{16*}, Pascal Lenain, MD^{17*}, Margaret Macro, MD^{18*}, Eric Voog, MD^{19*}, Lofti Benboubker, MD^{20*}, Olivier Allangba, MD^{21*}, Eric Jourdan, MD^{22*}, Mohamad Mohty, MD, PhD²³, **Herve Avet Loiseau, MD, PhD²⁴**, Claire Mathiot, MD^{2*} and **Michel Attal, MD, PhD²⁵**

¹Service d'Hématologie et Thérapie Cellulaire, Hopital Saint Antoine, Paris, France

²Institut Curie, Paris, France

³INSERM, Paris, France

⁴Hematology Department, IUCT–Oncopole, Toulouse, France

⁵Hematology department, CHU Rennes, Rennes, France
⁶CHU Dijon, Dijon, France
⁷Hôpital Claude Huriez, CHRU Lille, Lille, France
⁸Ch Lyon Sud, Pierre Bénite, France
⁹Hôpitaux De Brabois, Vandoeuvre Les Nancy, France
¹⁰Hôpital Hotel Dieu Et Hme, Nantes, France
¹¹CHU Bordeaux, Bordeaux, France
¹²Institut J Paoli–Calmettes, Marseille, France
¹³Hematology Department, Amiens University Hospital, Amiens, France
¹⁴CHU clermont ferrand, Clermont Ferrand, France
¹⁵University Hospital, La Roche–sur–Yon, France
¹⁶Centre Hospitalier de la côte basque, Bayonne, France
¹⁷Hematology department, Centre Henri Becquerel, Rouen, France
¹⁸Haematology Department, Caen University Hospital, Caen, France
¹⁹Centre hospitalier de le Mans, Le Mans, France
²⁰CHU Tours Hopital Bretonneau, Tours, France
²¹Centre Hospitalier de Saint Briec, Saint Briec, France
²²Clinical Hematology, Nimes University Hospital, Nîmes, France
²³Service d'Hématologie Clinique et Thérapie Cellulaire, Hopital Saint Antoine, Paris, France
²⁴Hopital Rangueil, Toulouse, France
²⁵IUCT–Oncopole, Toulouse, France

1690 – Impact of Red Blood Cell Transfusion Intensity on Progression–Free Survival in Lower–Risk MDS Patients Included in the European Leukemianet MDS Registry

Program: Oral and Poster Abstracts

Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Louise De Swart, MD^{1*}, Simon Crouch, MSc, PhD^{2*}, Marlijn Hoeks, MD^{3*}, Alex Smith, PhD^{4*}, Saskia Langemeijer, MD, PhD^{5*}, Pierre Fenaux, MD, PhD⁶, Argiris Symeonidis, MD, PhD⁷, Jaroslav Cermak, MD, PhD⁸, Reinhard Stauder, MD^{9*}, Moshe Mittelman, MD¹⁰, Guillermo Sanz, MD, PhD¹¹, Eva Hellstrom–Lindberg, MD, PhD¹², Luca Malcovati, MD¹³, Mette Skov Holm, MD, PhD^{14*}, Ulrich Germing, MD^{15*}, Krzysztof Madry, MD, PhD^{16*}, Antonio Medina de Almeida, MD, PhD^{17*}, Aurelia Tatic, MD^{18*}, Aleksandar Savic^{19*}, Njetočka Gredelj–Šimec, MD^{20*}, Agnes Guerci Bresler^{21*}, Dominic Culligan, MD^{22*}, Raphael Itzykson, MD, PhD²³, **Odile Beyne–Rauzy, MD^{24*}**, Sophie Park, MD, PhD^{25*}, Corine van Marrewijk, Ph.D.^{1*}, Nicole M A Blijlevens²⁶, David T. Bowen, MD²⁷ and T. M. de Witte, MD, PhD²⁸

¹Hematology, Radboudumc, Nijmegen, Netherlands

²Epidemiology and Cancer Statistics Group, Department of Health Sciences,, University of York, York,

York, United Kingdom

³Centre for Clinical Transfusion Research, Sanquin Research, Leiden, Sanquin, Eersel, Netherlands

⁴Epidemiology and Cancer Statistics Group, University of York, York, United Kingdom

⁵Radboudumc, Nijmegen, Netherlands

⁶Hôpital St Louis/ Paris 7 University, PARIS, FRA

⁷University of Patras, Medical School, Patras, Greece

⁸Institute of Hematology and Blood Transfusion, Prague, Czech Republic

⁹Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria

¹⁰Department of Internal Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

¹¹Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain

¹²Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

¹³Department of Hematology Oncology & Molecular Medicine, University of Pavia Medical School, Piazzale Golgi, Italy

¹⁴Aarhus Sygehus, Aarhus Universitetshospital, Aarhus, DNK

¹⁵Dept. of Hematology, Oncology and clinical Immunology, Heinrich–Heine–University Düsseldorf, Düsseldorf, Germany

¹⁶Medical University of Warsaw, Warszawa, POL

¹⁷Hospital da Luz, Lisbon, Portugal

¹⁸Center of Hematology and Bone Marrow Transplantation,, Fundeni Clinical Institute, Bucharest, Romania

¹⁹Clinic of Hematology, Clinical Center Vojvodina, University of Novi Sad, Novi Sad, YUG

²⁰Internal Medicine, Division of Hematology,, Merkur University Hospital, Zagreb, Croatia

²¹Service d'Hématologie,, Centre Hospitalier Universtaire Brabois Vandoeuvre, Nancy, France

²²Dep. of Haematology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom

²³Hopital Saint–Louis, Paris, France

²⁴Service d'hématologie, Centre Hospitalier Universitaire de Purpan, Toulouse, France

²⁵Department of Hematology, CHU Grenoble, Grenoble Cedex 9, France

²⁶Radboud University Medical Center Nijmegen, Nijmegen, Netherlands

²⁷Leeds Teaching Hospitals, Leeds, GBR

²⁸Radboud University Medical Centre, Nijmegen, Netherlands

155 – Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE–LY–004 Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies:

Mantle Cell Lymphoma, New Therapies

Saturday, December 9, 2017: 1:00 PM

Bldg A, Lvl 4, A411–A412 (Georgia World Congress Center)

Michael Wang, MD¹, *Simon Rule, MD^{2*}*, *Pier Luigi Zinzani, MD, PhD³*, *Andre Goy, MD⁴*, *Rene-Olivier Casasnovas, MD^{5*}*, *Stephen D. Smith, MD⁶*, *Gandhi Damaj, MD⁷*, *Jeanette K. Doorduijn, MD, PhD⁸*, *Thierry Lamy, Pr, MD, PhD⁹*, *Franck Morschhauser, MD, PhD^{10*}*, *Carlos Panizo, MD, PhD^{11*}*, *Bijal Shah, MD¹²*, *Andrew Davies, PhD^{13*}*, *Richard Eek, MBChB^{14*}*, *Jehan Dupuis, MD^{15*}*, *Eric Jacobsen, MD¹⁶*, *Arnon P. Kater, MD, PhD¹⁷*, *Steven Le Gouill, MD PhD^{18*}*, **Lucie Oberic, MD^{19*}**, *Tadeusz Robak, MD, PhD²⁰*, *Todd Covey, PhD^{21*}*, *Richa Dua, PharmD^{21*}*, *Ahmed Hamdy, MD²¹*, *Xin Huang^{21*}*, *Raquel Izumi, PhD²¹*, *Priti Patel, MD^{21*}*, *J. Greg Slatter, PhD^{21*}* and *Wojciech Jurczak, PhD, MD²²*

¹Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX

²Plymouth University Medical School, Plymouth, United Kingdom

³Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy

⁴John Theurer Cancer Center, Hackensack Meridian Health, New York, NY

⁵Hopital d'Enfants, CHU Dijon, Dijon, France

⁶Fred Hutchinson Cancer Research Center, Seattle, WA

⁷Institut d'Hematologie de Basse-Normandie, Caen, France

⁸Erasmus MC, Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands

⁹CHU Rennes, Rennes, France

¹⁰CHRU Lille – Hôpital Claude Huriez, Lille, France

¹¹Clínica Universidad de Navarra, Pamplona, Spain

¹²Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

¹³Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

¹⁴Border Medical Oncology, Wodonga, Australia

¹⁵Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France

¹⁶Dana-Farber Cancer Institute, Boston, MA

¹⁷Academic Medical Center, Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands

¹⁸CHU de Nantes – Hotel Dieu, Nantes, France

¹⁹Institut Universitaire de Cancer-Oncopole (IUCT-O), Toulouse, France

²⁰Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland

²¹Acerta Pharma, Redwood City, CA

²²Department of Haematology, Jagiellonian University, Krakow, Poland

736 – PET–Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First–Line Treatment of Unfavorable Early–Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa–FIL–EORTC Intergroup

Program: Oral and Poster Abstracts

Type: Oral

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma—Chemotherapy and PET Studies

Monday, December 11, 2017: 3:30 PM

Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)

Luc–Matthieu Fornecker^{1*}, Julien Lazarovici, MD^{2*}, Igor Aurer, PhD^{3*}, Rene–Olivier Casasnovas, MD^{4*}, Anne–Claire Gac^{5*}, Christophe Bonnet, MD, PhD^{6*}, Krimo Bouabdallah, MD^{7*}, Aurore Perrot, MD^{8*}, Lena Specht^{9*}, Mohamed Touati^{10*}, Jean Claude Eisenmann^{11*}, **Cecile Borel, MD**^{12*}, Aspasia Stamatoullas, MD^{13*}, Emmanuelle Nicolas–Virelizier, MD^{14*}, Laurent Pascal^{15*}, Pieterella Lugtenburg^{16*}, Monica Bellei, MSc, PhD^{17*}, Alexandra traverse–Glehen, MD, PhD^{18*}, Christiane Copie, MD PhD^{19*}, Martin Hutchings, MD, PhD^{20*}, Annibale Versari^{21*}, Michel Meignan^{22*}, Massimo Federico²³ and Marc Andre, MD^{24*}

¹Haematology, University Hospital, Strasbourg, France

²Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France

³CHC ZAGREB, ZAGREB, Croatia

⁴CHU Dijon, Dijon, FRA

⁵Department of Haematology, Caen, France

⁶Clinical Hematology, CHU University of Liège, Liège, BEL

⁷University Hospital of Bordeaux, Pessac, France

⁸Hôpitaux De Brabois, Vandoeuvre Les Nancy, France

⁹Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark

¹⁰Hôpital Dupuytren, Limoges Cedex 1, FRA

¹¹Centre Hospitalier de Mulhouse, MULHOUSE, FRA

¹²Service d'Hématologie, Institut Universitaire du Cancer de Toulouse – CHU de Toulouse, Toulouse, France

¹³INSERM U1245, Centre Henri Becquerel, Rouen, France

¹⁴Centre Léon Bérard, Lyon, France

¹⁵HOPITAL SAINT VINCENT, LILLE CEDEX, FRA

¹⁶Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands

¹⁷Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena, Modena, Italy

¹⁸Pathology Department, CHU Lyon, Lyon, France

¹⁹Pathology Department, CHU Henri Mondor, AP HP, Paris, France

²⁰Rigshospitalet, Copenhagen University Hospital, Copenhagen, DNK

²¹S.C. Medicina Nucleare – Centro PET, A.O. Arcispedale S. Maria Nuova, Reggio Emilia, Italy

²²Hôpital Henri Mondor, Créteil, FRA

²³Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy

²⁴Department of Hematology, Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

1843 – Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Richez Valentine^{1*}, **Stephanie Guidez**^{2*}, **Isabelle Azais**^{3*}, **Geraldine Durand, MD**^{3*}, **Vincent Javaugue, MD**^{4*}, **Antoine Brigaud, MD**^{5*}, **Florent Plasse, MD**^{6*}, **Jeremie Diolez, MD**^{7*}, **Antoine Machet**^{8*}, **Niels Moya**^{9*}, **Cécile Gruchet**^{8*}, **Arthur Bobin**^{8*}, **Anthony Levy**^{8*}, **Florence Sabirou**^{8*}, **Anthony Bonnin, MD**^{10*}, **Celine Dieval, MD**^{11*}, **Sylvain Primault, MD**^{12*}, **Jocelyn Barrier, MD**^{13*}, **Emmanuel Fleck, MD**^{14*}, **Claire Daras, MD**^{15*}, **Isabelle Princet, MD**^{16*}, **Delphine Bauwens, MD**^{16*}, **Guillemette Fouquet**^{17*}, **Frank Bridoux, MD, PhD**^{18*}, **Herve Avet Loiseau, MD, PhD**¹⁹ and **Xavier Leleu, MD, PhD**²⁰

¹Hematology, Nice Sophia Antipolis University, NICE, FRA

²Hematology, Poitiers University Hospital / INSERM CIC 1402, Poitiers, France

³Rheumatology, Poitiers University Hospital, Poitiers, France

⁴Nephrology, Poitiers University Hospital, Poitiers, France

⁵Rheumatology, Angouleme Hospital, Angouleme, France

⁶Nephrology, Saintonge Hospital, SAINTES, France

⁷Nephrology, Angouleme Hospital, Angouleme, France

⁸Hematology, Poitiers University Hospital, Poitiers, France

⁹Service d'Hématologie et de thérapie cellulaire, CHU de Poitiers, Poitiers, France

¹⁰Hematology, Royan Hospital, Royan, France

¹¹Rochefort Hospital, Rochefort, France

¹²Hematology, Chatellerault Hospital, Chatellerault, France

¹³Chatellerault, Chatellerault, France

¹⁴Hematology, La Rochelle Hospital, La Rochelle, France

¹⁵Poitiers University Hospital, Poitiers, France

¹⁶Pharmacy, Poitiers University Hospital, Poitiers, France

¹⁷Maladies du Sang, Hôpital Claude Huriez, CHRU Lille, Lille, France

¹⁸Department of Nephrology and National Referral Center for AL Amyloidosis, CHU, Poitiers, France

¹⁹University Hospital Toulouse, Toulouse, FRA

²⁰Service D'Hématologie Et Thérapie Cellulaire, Service D'Hématologie Et Thérapie Cellulaire, Poitiers, France

1496 – R–DHA–Oxaliplatin before Autologous Stem Cell Transplantation Prolongs PFS and OS As Compared to R–DHA–Carboplatin and R–DHA–Cisplatin in Patients with Mantle Cell Lymphoma, a Subgroup Analysis of the LyMa Trial

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B–Cell Lymphoma—Clinical Studies: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Steven Le Guill, MD, PhD^{1,2*}, Catherine Thieblemont, MD, PhD³, **Lucie Oberic, MD^{4*}**, Krimo Bouabdallah, MD^{5*}, Emmanuel Gyan, MD, PhD⁶, Gandhi Damaj, MD⁷, Thomas Gastinne, MD^{8*}, Vincent Ribrag⁹, Carla Araujo, MD^{10*}, Eric Deconinck, MD, PhD¹¹, Joel Fleury, MD^{12*}, Pierre Morel, MD¹³, Emmanuelle Nicolas–Virelizier, MD^{14*}, Reda Bouabdallah, MD^{15*}, Jamilé Frayfer, MD^{16*}, Eric Jourdan, MD^{17*}, Richard Delarue, MD¹⁸, Laurence Sahnes^{19*}, Alain Delmer²⁰, Anne Moreau, MD^{21*}, Marie C Bene, PharmD, DPhil^{22*}, Gilles Andre Salles, MD, PhD²³, Herve Tilly²⁴, Thierry Lamy, Pr, MD, PhD²⁵, Remy Gressin, MD²⁶ and Olivier Hermine, MD, PhD^{27*}

¹Department of Hematology, Nantes University Hospital, Nantes, France

²CHU de Nantes, INSERM UMR 892 équipe 10, Nantes, France

³Hematology, CHU Paris–GH St–Louis Lariboisiere F. Widal–Hopital, Saint Louis, Paris, FRA

⁴Department of Hematology, Purpan University Hospital, Toulouse, France

⁵Haematology, CHU de Bordeaux, Bordeaux, France

⁶Service d'Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire, Tours, France

⁷Service d'Hématologie, CHU Caen, Caen, France

⁸Clinical Hematology, Nantes University Hospital, Nantes, France

⁹Gustave Roussy Cancer Campus, Villejuif, France

¹⁰Centre Hospitalier de la Cote Basque, Bayonne, France

¹¹Hematology, INSERM UMR1098 – CHU Jean Minjoz, Besancon, France

¹²Haematology, Pole sante republicque, Clermont ferrand, France

¹³Hematology, CH, Lens, France

¹⁴Onco–hematology, Centre Leon Berard, University Claude Bernard Lyon 1, Lyon, France

¹⁵Institut Paoli Calmettes, Department of Hematology, Marseille, France

¹⁶Hématologie, Meaux Hospital, Meaux, France

¹⁷Clinical Hematology, Nimes University Hospital, Nîmes, France

¹⁸Hematology Department / Hemophilia Center, Necker University Hospital, AP–HP, Paris, France

¹⁹CH perpignan, perpignan, France

²⁰Hematology Department, University Hospital, Reims, France, Reims, France

²¹Pathology Department, Nantes University Hospital, Nantes, France

²²Hematology Laboratory, Nantes University Hospital, Nantes, France

²³Hematology, Hospices Civils de Lyon – Université de Lyon, Pierre-Bénite, France

²⁴Hematology Department, Centre Henri Becquerel, Rouen, France

²⁵INSERM U917, CHU Pontchaillou, Rennes, France

²⁶Hematology, CHU Grenoble, Grenoble, France

²⁷Hôpital Universitaire Necker-Enfants Malades, Paris, France

4599 – RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention – Final Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO – SFGM-TC French intergroup)

Program: Oral and Poster Abstracts

Session: 732. Clinical Allogeneic Transplantation: Results: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Olivier Tournilhac, MD, PhD^{1*}, Magali Le Garff-Tavernier^{2*}, Reza Tabrizi, MD^{3*}, Stephanie Nguyen-Quoc^{4*}, Faezeh Legrand-Izadifar^{5*}, Patricia Combes^{6*}, Patrice Chevallier, MD^{7*}, Oumedaly Reman, MD^{8*}, Cecile Tomowiak, MD^{9*}, **Cecile Borel, MD^{10*}**, Sylvie François^{11*}, Pascal Turlure^{12*}, Sebastien Maury, MD, PhD^{13*}, Gaelle Guillerm, MD^{14*}, Laure Vincent^{15*}, Karin Bilger^{16*}, Richard Lemal, MD^{17*}, Romain Guieze, MD, PhD^{18*}, Claire Quiney^{19*}, Aurelie Cabrespine, PhD^{20*}, Jacques-Olivier Bay, MD, PhD²¹, Veronique Leblond²² and Nathalie Dhedin, MD^{23*}

¹Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU, Université Clermont Auvergne, EA7453 CHELTER, CIC501, Clermont Ferrand, France

²UPMC Paris 6-INSERM UMRS 1138, Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

³Hôpital Haut-Leveque C.H.U. de Bordeaux, Pessac, France

⁴Service d'hématologie clinique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

⁵Service d'hématologie clinique, département de greffe de moelle, CHU Nice, Nice, France

⁶Service cytogénétique, CHU Estaing, Clermont-Ferrand, France, Clermont-Ferrand, France

⁷Hematology, Hôpital Hôtel Dieu, Nantes, France

⁸Chu Cote De Nacre, Caen, FRA

⁹Department of Oncology-Haematology and Cell Therapy, CHU, Poitiers, INSERM, Inserm CIC 1402, Poitiers, France, Poitiers, France

¹⁰Service d'Hématologie, Institut Universitaire du Cancer de Toulouse – CHU de Toulouse, Toulouse, France

¹¹Service Maladies du sang, CHU Angers, Angers, France, Angers, France

¹²Service de thérapie cellulaire et d'hématologie clinique adulte, CHU Dupuytren,, Limoges, France

¹³Henri Mondor University Hospital, Creteil, France

¹⁴Hematologie Clinique, Brest, FRA

¹⁵Département Hématologie Clinique, Hôpital St Eloi,, Montpellier, France

¹⁶Department of hematology, CHU Strasbourg, Strasbourg, FRA

¹⁷university hospital of Clermont–Ferrand, Unit of adult cell therapy and clinical hematology, Clermont Ferrand, France

¹⁸Clermont Ferrand University Hospital, Clermont Ferrand, FRA

¹⁹Service d'Hématologie Biologique, Groupe Hospitalier Pitié–Salpêtrière, Paris, France

²⁰Service d'Hématologie et de Therapie Cellulaire, CHU, Clermont–Ferrand, France

²¹Service d'Hématologie Clinique et de Therapie Cellulaire, CHU, Universite d'Auvergne, EA7453, CIC501, Clermont–Ferrand, FRA

²²AP–HP Hôpital Pitié–Salpêtrière, Paris, France

²³Department of Hematology, University Hospital Saint–Louis, PARIS, France

4118 – A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC–122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B–Cell Lymphoma Subjects: Results from the Phase I CC–122–ST–001 Study

Program: Oral and Poster Abstracts

Session: 626. Aggressive Lymphoma (Diffuse Large B–Cell and Other Aggressive B–Cell Non–Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Cecilia Carpio, MD^{1*}, Reda Bouabdallah, MD^{2*}, **Loïc Ysebaert, MD, PhD^{3*}**, Juan–Manuel Sancho, MD, PhD^{4*}, Gilles Andre Salles, MD, PhD⁵, Raul Cordoba, MD, PhD^{6*}, Antonio Pinto, MD^{7*}, Mecide Gharibo, MD^{8*}, Drew W. Rasco, MD^{9*}, Carlos Panizo, MD, PhD^{10*}, Jose A. Lopez–Martin, MD, PhD^{11*}, Armando Santoro, MD^{12*}, Antonio Salar, MD, PhD^{13*}, Silvia Damian, MD^{14*}, Alejandro Martín, MD, PhD^{15*}, Gregor Verhoef, MD, PhD^{16*}, Xin Wei^{17*}, Patrick R. Hagner, PhD^{18*}, Kristen Hege, MD¹⁹, Alberto Risueño, PhD^{20*}, Anita K. Gandhi, PhD¹⁸, Tonia J. Buchholz, PhD^{19*}, Michael Pourdehnad, MD¹⁹ and Vincent Ribrag, MD²¹

¹Hospital Universitario Vall d´Hebron, Barcelona, Spain

²Institut Paoli–Calmettes, Marseille, France

³Centre Hospitalier Universitaire de Toulouse, Toulouse, France

⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain

⁵Centre Hospitalier Lyon–Sud, Pierre–Bénite, France

⁶Hosp. Fundación Jimenez Díaz, Madrid, Spain

⁷Istituto Nazionale Tumori, Fondazione Pascale, Napoli, Italy

⁸The Cancer Institute of New Jersey, New Brunswick, NJ

⁹South Texas Accelerated Research Therapeutics LLC, San Antonio, TX

¹⁰Clínica Universidad de Navarra, Pamplona, Spain

¹¹12 de Octubre University Hospital & Research Institute; GETICA, Madrid, Spain

¹²*Instituto Clinico Humanitas, Milano, Italy*

¹³*Hospital del Mar, Barcelona, Spain*

¹⁴*Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy*

¹⁵*Hospital Universitario de Salamanca and IBSAL, Salamanca, Spain*

¹⁶*UZ Gasthuisberg Leuven, Leuven, Belgium*

¹⁷*Celgene Corporation, Berkeley Heights, NJ*

¹⁸*Celgene Corporation, Summit, NJ*

¹⁹*Celgene Corporation, San Francisco, CA*

²⁰*Celgene Institute for Translational Research Europe, Seville, Spain*

²¹*Institut Gustave Roussy, Villejuif, France*

2572 – B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with t(5;14)(q31;q32)/IL3-IGH Rearrangement and Eosinophilia: A Peculiar IGH BCP-ALL

Program: Oral and Poster Abstracts

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Benjamin Fournier^{1*}, Estelle Balducci, PharmD^{2*}, Nicolas Duployez, PharmD, PhD^{3,4*}, Emmanuelle Clappier, PharmD, PhD^{5*}, Wendy Cucchini^{6*}, Elodie Bottolier-Colomb, MD^{7*}, Denis Caillot, MD^{8*}, Helene Cave, PharmD, PhD^{9*}, Aurélie Caye-Eude, PharmD^{10*}, **Eric Delabesse, MD, PhD^{11*}**, Coralie Derrieux, PharmD^{12*}, Nathalie Dhedin, MD^{13*}, Florent Dumezy, MD^{14*}, Pascaline Etancelin, PharmD^{15*}, Odile Fenneteau, MD^{16*}, Jamilé Frayfer, MD^{17*}, Antoine Gourmel, MD^{18*}, Marie Loosveld, MD, PhD^{19*}, Gerard Michel, MD^{20*}, Nathalie Nadal^{21*}, Claire-Helene Oudin^{20*}, Dominique Penther, MD^{15*}, Isabelle Tigaud, MD^{22*}, Nathalie Grardel, MD^{23*}, Marine Lafage, MD^{2*} and Andre Baruchel, MD²⁴

¹, University Hospital Robert Debré, Assistance Publique – Hôpitaux de Paris, PARIS, FRA

²Department of Genetics, La Timone Hospital, Aix Marseille University, MARSEILLE, France

³Department of Hematology, University of Lille, Lille, France

⁴Laboratory of Hematology, CHU Lille, Lille, France

⁵Hematology Laboratory, University Hospital Saint-Louis, APHP, Paris, FRA

⁶Hematology Laboratory and INSERM U944, Hopital Saint-Louis, Paris, France

⁷Department of Pediatric Oncology and Hematology, University Hospital of Dijon, DIJON, France

⁸Department of Hematology, University Hospital of Dijon, Dijon, France

⁹Department of Genetics, University Hospital Robert Debré, Paris, FRA

¹⁰Department of Genetics, University Hospital Robert Debré, PARIS, France

¹¹Department of Hematology, University Hospital Purpan, TOULOUSE, FRANCE

¹²Hematology Laboratory, Hospital Saint Faron, MEAUX, France

¹³Department of Hematology, University Hospital Saint-Louis, PARIS, France

¹⁴Department of Hematology, University Hospital, Lille, Lille, France

¹⁵Department of Oncology Genetics, Henri Becquerel Center, ROUEN, France

¹⁶Laboratoire d'Hématologie, Hôpital Robert Debré, APHP, Paris, France

¹⁷Department of Hematology, Hospital Saint Faron, MEAUX, France

¹⁸Department of Pediatric Oncology, Hematology, Immunology, University Hospital of Amiens, AMIENS, France

¹⁹Hematology Laboratory, La Timone Hospital, Aix Marseille University, MARSEILLE, France

²⁰Department of Pediatric Hematology, Aix Marseille University, Marseille, France

²¹Department of Genetics, University Hospital, Dijon, DIJON, France

²²Department of Cytogenetics, Lyon-Sud Hospital, LYON, France

²³Department of Hematology, University Hospital, Lille, LILLE, France

²⁴Service d'Hématologie et Oncologie pédiatrique, Hôpital Robert Debré, Paris, France

1877 – Prognostic Significance of Plasmablastic Plasma Cells in the Era of Novel Agents in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Antoine Machet^{1*}, **Stephanie Guidez**^{1*}, **Guillemette Fouquet**^{2*}, **Thomas Systchenko**^{1*}, **Deborah Desmier**^{1*}, **Niels Moya**^{1*}, **Cécile Gruchet**^{1*}, **Anthony Levy**^{1*}, **Florence Sabirou**^{1*}, **Arthur Bobin**^{1*}, **Valentine Richez**, MD^{3*}, **Celine Dieval**, MD^{4*}, **Carine Motard**^{5*}, **Florence Borde**^{6*}, **Geraldine Durand**, MD^{7*}, **Isabelle Azais**^{8*}, **Vincent Javaugue**, MD^{9*}, **Cecile Tomowiak**, MD^{1*}, **Sabrina Bouyer**^{10*}, **Ouda Ghoul**^{10*}, **Elodie Dindinaud**^{10*}, **Frank Bridoux**, MD, PhD^{11*}, **Pieter Sonneveld**, MD, PhD¹², **Herve avet Loiseau**, MD, PhD¹³ and **Xavier Leleu**, MD, PhD¹

¹Department of Oncology–Haematology and Cell Therapy, CHU, Poitiers, INSERM, Inserm CIC 1402, Poitiers, France, Poitiers, France

²Hematology, CHU Lille, Lille, France

³Hematology, CHU Nice, Nice, France

⁴Rochefort Hospital, Rochefort, France

⁵Department of Internal Medicine, CH, Niort, France, niort, France

⁶Oncology, CH Saintonge, Saintes, France

⁷Rheumatology, Poitiers University Hospital, Poitiers, France

⁸Rheumatology, CHU Poitiers, Poitiers, France

⁹Nephrology, Poitiers University Hospital, Poitiers, France

¹⁰Hematology Laboratory, CHU Poitiers, Poitiers, France

¹¹Department of Nephrology and National Referral Center for AL Amyloidosis, CHU, Poitiers, France

¹²Erasmus Medical Center Rotterdam, Rotterdam, Netherlands

¹³IUCT ONCOPOLE, Toulouse, FRA

330 The Genomic Landscape of Multiple Myeloma Complex Structural Variations

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics

Sunday, December 10, 2017: 8:45 AM

Bldg B, Lvl 3, B302–B303 (Georgia World Congress Center)

Francesco Maura^{1,2*}, **Niccolò Bolli**^{1,3,4*}, **Kevin J Dawson**^{1*}, **Nicos Angelopoulos**, PhD^{1*}, **Stephane Minvielle**^{5*}, **Inigo Martincorena**^{1*}, **Thomas J Mitchell**^{1*}, **Anthony Fullam**^{1*}, **Santiago Gonzalez**^{6*}, **Dominik Glodzik**^{1*}, **Raphael Szalat**, MD^{7*}, **Mehmet Kemal Samur**, PhD⁸, **Mariateresa Fulciniti**, PhD⁹, **Yu-Tzu Tai**, PhD¹⁰, **Florence Magrangeas**^{5*}, **Philippe Moreau**^{11*}, **Paolo Corradini**, MD^{3,12}, **Kenneth C. Anderson**, MD¹³, **David Wedge**, PhD^{14*}, **Moritz Gerstung**, PhD^{6*}, **Hervé Avet-Loiseau**, MD, PhD^{15*}, **Nikhil Munshi**, MD⁷ and **Peter J Campbell**, MD, PhD^{1*}

¹Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

²Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, Italy

³Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

⁴Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

⁵Université de Nantes, Nantes, France

⁶European Bioinformatics Institute, Hinxton, United Kingdom

⁷Dana-Farber Cancer Institute, Boston, MA

⁸Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

¹⁰Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston

¹¹Department of Hematology, Nantes University Hospital, Nantes, France

¹²University of Milan, Milan, Italy

¹³Dana-Farber Cancer Institute, Harvard Medical School, Boston

¹⁴Big Data Institute, University of Oxford, Oxford, United Kingdom

¹⁵Genomics of Myeloma Laboratory, L'Institut Universitaire du Cancer Oncopole, Toulouse, France

2191 – Socioeconomic Outcomes Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881

Program: Oral and Poster Abstracts

Session: 904. Outcomes Research—Malignant Conditions: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Melissa Barbat^{1*}, Michal Kicinski^{2*}, **Stefan Suciu^{2*}**, Yves Benoit^{3*}, Françoise Mazingue^{1*}, Teresa De Rojas, MD^{4*}, Els Vandecruys^{3*}, **Geneviève Plat^{5*}**, Anne Uyttebroeck^{6*}, Patric Lutz^{7*}, Marie-Françoise Dresse^{8*}, Pauline Simon^{9*}, Claire Pluchart^{10*}, Odile Minckes^{11*}, Alina Ferster, MD¹², Claire Freycon^{13*}, Frédéric Millot^{14*}, Jutte Van Der Werff^{15*}, Christophe Chantrain^{16*}, Robert Paulus^{17*}, Pierre Rohrllich^{18*} and Caroline Piette^{8*}

¹Department of Pediatric Hematology–Oncology, CHRU Lille, Lille, France

²Statistics Department, EORTC Headquarters, Brussels, Belgium

³Department of Pediatric Hematology–Oncology, Ghent University Hospital, Ghent, Belgium

⁴Medical and TRI Department, EORTC, Brussels, Belgium

⁵Department of Hematology, CHU Toulouse, Toulouse, France

⁶Center for Human Genetics, University Hospital Leuven, Leuven, Belgium

⁷Department of Pediatric Hematology–Oncology, CHRU Strasbourg, Strasbourg, France

⁸Department of Pediatric Oncology, CHR Citadelle, Liège, Belgium

⁹Pediatric Oncology, CHRU Besançon, Besançon, France

¹⁰Department of Pediatric Haematology and Oncology, CHU Reims, Reims, France

¹¹Department of Pediatric Hematology–Oncology, CHU Caen, Caen, France, CHU Caen, Caen, France

¹²Department of hemato oncology, HUDERF (ULB), Bruxelles, BEL

¹³Department of Pediatric Hematology–Oncology, CHU Grenoble, Grenoble, France

¹⁴Department of Pediatric Hematology–Oncology, CHU Poitiers, Poitiers, France

¹⁵VUB, Brussels, Belgium

¹⁶CHC Espérance, Liège, Belgium

¹⁷CHR Verviers East Belgium, Verviers, Belgium

¹⁸Pediatric Oncology, CHU Nice, Nice, France

4378 – Abnormalities in Mitochondrial DNA Copy Number Have Pathogenetic and Prognostic Implications in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Yanira Ruiz-Heredia^{1*}, *Mehmet Kemal Samur*, PhD^{2,3}, *Alejandra Ortiz-Ruiz*^{1*}, *Rafael Alonso Fernández*^{4*}, *Beatriz Sanchez-Vega*^{5*}, *Alberto Blazquez*^{6*}, *Aitor Delmiro*^{6*}, *Jose Carlos Martinez-Avila*^{7*}, *Esther Onecha*^{1*}, *Antonio Valeri*, PhD^{8*}, *Miguel Angel Martin*^{6*}, *Niccolo Bolli*, MD⁹, *Yu-Tzu Tai*, PhD¹⁰, *Francesco Maura*^{11*}, *Raphael Szalat*, MD^{12*}, *Mariateresa Fulciniti*, PhD¹³, *María Linares*, PhD^{1*}, *Miguel Gallardo*, PhD^{14*}, *Peter J Campbell*, MD, PhD^{11*}, *Hervé Avet-Loiseau*^{15*}, *Juan Jose Lahuerta*^{16*}, *Nikhil Munshi*, MD¹² and *Joaquin Martinez-Lopez*, MD, PhD^{1*}

¹Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain

²Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

³Dana-Farber Cancer Institute/ Harvard Medical School, Boston, MA

⁴Hospital Universitario 12 de Octubre, Madrid, Spain

⁵Department of Hematology, Hospital 12 de Octubre, CIBERONC, Madrid, Spain

⁶Laboratorio de enfermedades mitocondriales y neuromusculares. Instituto de Investigación Hospital 12 de Octubre (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain

⁷Clinical Pharmacology Department (IdiPAZ), Hospital Universitario La Paz, Madrid, Spain

⁸Department of Hematology, Hospital Universitario La Paz, Madrid, Spain

⁹Cancer genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

¹⁰Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston

¹¹Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

¹²Dana-Farber Cancer Institute, Boston, MA

¹³Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

¹⁴Department of Hematology, Hospital Universitario 12 de Octubre, CNIO, Complutense University, Madrid, Spain

¹⁵Unit for Genomics in Myeloma, Institut Universitaire du Cancer, Toulouse, France

¹⁶Department of Hematology, Hospital 12 de Octubre, Madrid, Spain

2563 – Fertility Status Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881

Program: Oral and Poster Abstracts

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Teresa De Rojas, MD^{1*}, Michal Kicinski^{2*}, **Stefan Suciu**², Yves Benoit^{3*}, Françoise Mazingue^{4*}, Els Vandecruys^{3*}, **Geneviève Plat**^{5*}, Anne Uyttebroeck^{6*}, Patric Lutz^{7*}, Marie-Françoise Dresse^{8*}, Pauline Simon^{9*}, Claire Pluchart^{10*}, Odile Minckes^{11*}, Alina Ferster, MD¹², Claire Freycon^{13*}, Frédéric Millot^{14*}, Jutte Van Der Werff^{15*}, Christophe Chantrain^{16*}, Robert Paulus^{17*}, Pierre Rohrlich^{18*} and Caroline Piette^{8*}

¹Medical and TRI Department, EORTC, Brussels, Belgium

²Statistics Department, EORTC Headquarters, Brussels, Belgium

³Department of Pediatric Hematology–Oncology, Ghent University Hospital, Ghent, Belgium

⁴Department of Pediatric Hematology–Oncology, CHRU Lille, Lille, France

⁵Department of Hematology, CHU Toulouse, Toulouse, France

⁶Center for Human Genetics, University Hospital Leuven, Leuven, Belgium

⁷Department of Pediatric Hematology–Oncology, CHRU Strasbourg, Strasbourg, France

⁸Department of Pediatric Oncology, CHR Citadelle, Liège, Belgium

⁹Pediatric Oncology, CHRU Besançon, Besançon, France

¹⁰Department of Pediatric Haematology and Oncology, CHU Reims, Reims, France

¹¹Department of Pediatric Hematology–Oncology, CHU Caen, Caen, France, CHU Caen, Caen, France

¹²Department of Hemato–Oncology, HUDERF (ULB), Brussels, Belgium

¹³Department of Pediatric Hematology–Oncology, CHU Grenoble, Grenoble, France

¹⁴Department of Pediatric Hematology–Oncology, CHU Poitiers, Poitiers, France

¹⁵VUB, Brussels, Belgium

¹⁶CHC Espérance, Liège, Belgium

¹⁷CHR Verviers East Belgium, Verviers, Belgium

¹⁸Pediatric Oncology, CHU Nice, Nice, France

2021 Ixazomib–Lenalidomide–Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM)

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Philippe Moreau^{1*}, Cyrille Hulin, MD^{2*}, Denis Caillot, MD^{3*}, Gerald Marit, MD^{4*}, Aurore Perrot, MD^{5*}, Laurent Garderet, MD, PhD⁶, Thierry Facon, MD^{7*}, Lofti Benboubker, MD^{8*}, Lionel Karlin, MD^{9*}, Mourad Tiab^{10*}, Bertrand Arnulf, MD, PhD^{11*}, Xavier Leleu, MD, PhD¹², Cyrille Touzeau, MD, PhD^{13*}, **Murielle Roussel**^{14*}, Lucie Planche^{15*}, **Hervé Avet-Loiseau**^{16*}, Thomas Dejoie^{17*} and **Michel Attal**, MD, PhD¹⁸

¹Hôpital Hotel Dieu Et Hme, Nantes, France

²hematology department, university hospital bordeaux, france, bordeaux, UT, France

³Department of Hematology, University Hospital of Dijon, Dijon, France

⁴CHU Bordeaux, Bordeaux, France

⁵Hôpitaux De Brabois, Vandoeuvre Les Nancy, France

⁶Service d'Hématologie et Thérapie Cellulaire, Hopital Saint Antoine, Paris, France

⁷Hopital C. Huriez, Lille, FRA

⁸university hospital, tours, France

⁹Ch Lyon Sud, Pierre Bénite, France

¹⁰University Hospital, La Roche-sur-Yon, France

¹¹university hospital saint-louis, Paris Cedex 10, France

¹²Hematology, Hôpital La Mileterie, Poitiers, France

¹³CHU de Nantes, Nantes, France

¹⁴Hematology Department, IUCT-Oncopole, Toulouse, France

¹⁵CHU, Nantes, France

¹⁶Unit for Genomics in Myeloma, Insitut Universitaire du Cancer, Toulouse, France

¹⁷university hospital, Nantes, France

¹⁸IUCT-Oncopole, Toulouse, France

1771 Biological and Prognostic Impact of Apobec-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Francesco Maura^{1,2*}, Mia Petljak^{1*}, Marta Lionetti^{3,4*}, Ingrid Cifola^{5*}, Winnie Liang, PhD^{6*}, Eva Pinatel^{5*}, Ludmil Alexandrov^{7*}, Anthony Fullam^{1*}, Inigo Martincorena^{1*}, Kevin J Dawson^{1*}, Nicos Angelopoulos, PhD^{1*}, Raphael Szalat, MD^{8*}, Paolo Corradini, MD^{9,10}, Kenneth C. Anderson, MD¹¹, Stephane Minvielle^{12*}, Mehmet K. Samur, PhD^{11*}, Antonino Neri^{3,4*}, **Hervé Avet-Loiseau, MD, PhD^{13*}**, Jonathan J. Keats, PhD⁶, Peter J Campbell, MD, PhD^{1*}, Nikhil Munshi, MD⁸ and Niccolò Bolli^{1,4,10*}

¹Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

²Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, Italy

³Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

⁴Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

⁵Institute for Biomedical Technologies, National Research Council, Milan, Italy

⁶Translational Genomics Research Institute, Phoenix, AZ

⁷Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los Alamos

⁸Dana-Farber Cancer Institute, Boston, MA

⁹University of Milan, Milan, Italy

¹⁰Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

¹¹Dana-Farber Cancer Institute, Harvard Medical School, Boston

¹²Université de Nantes, Nantes, France

¹³Genomics of Myeloma Laboratory, L'Institut Universitaire du Cancer Oncopole, Toulouse, France

29 – Early Detection of *WT1* minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

Program: Oral and Poster Abstracts

Type: Oral

Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic and predictive markers

Saturday, December 9, 2017: 8:45 AM

Bldg C, Lvl 2, C202–C204 (Georgia World Congress Center)

Juliette Lambert^{1*}, *Jérôme Lambert*, MD, PhD^{2*}, *Xavier Thomas*, MD³, *Alice Marceau-Renaut*, PharmD^{4*}, *Aline Renneville*, MD, PhD^{4*}, *Marie-Magdelaine Coude*, MD^{5*}, *Sandrine Hayette*, MD^{3*}, *Christian Recher*, MD, PhD⁶, *Emmanuel Raffoux*, MD^{7*}, *Arnaud Pigneux*, MD, PhD^{8*}, *Céline Berthon*, MD, PhD^{9*}, *Christine Terré*, PharmD, PhD^{10*}, *Karine Celli-Lebras*, CRA^{7*}, *Sylvie Castaigne*, MD^{1*}, *Nicolas Boissel*, MD, PhD², *Philippe Rousselot*, MD^{1,12*}, *Herve Dombret*, MD² and *Claude Preudhomme*, PharmD, PhD⁴

¹Versailles Hospital, University Paris-Saclay, Le Chesnay, France

²Saint-Louis University Hospital, University Paris Diderot, Paris, France

³Lyon-Sud University Hospital, Pierre Bénite, France

⁴Claude Huriez University Hospital, University Lille, Lille, France

⁵Cochin University Hospital, Paris, France

⁶Toulouse University Hospital, University Toulouse III, Toulouse, France

⁷Saint-Louis University Hospital, Paris, France

⁸Hematology Department, Centre Hospitalier Universitaire (CHU) de Bordeaux, Universités de Bordeaux, Bordeaux, France

⁹Claude Huriez University Hospital, Lille, France

¹⁰Versailles Hospital, Le Chesnay, France

¹¹Hôpital de Versailles, Le Chesnay, France

¹²Department of Hematology and Oncology, Centre Hospitalier de Versailles, INSERM UMR 1173, Université Versailles Saint-Quentin-en-Yvelines, Université Paris Saclay, Le Chesnay, France

3124 – Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Program: Oral and Poster Abstracts

Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Niels WCJ Van De Donk¹, Homer Adams III^{2*}, Greet Vanhoof^{3*}, Jakub Krejčík, MD^{4*}, Koen Van der Borgh^{3*}, Tineke Casneuf, PhD^{3*}, Tina Smets^{3*}, Amy Axel^{2*}, Yann Abraham^{3*}, Hugo Ceulmans^{3*}, Frederik Stevenaert^{3*}, Saad Z Usmani, MD⁵, Torben Plesner, MD⁴, Sagar Lonial, MD⁶, Berris van Kessel-Welmers^{1*}, Henk M Lokhorst^{1*}, Tuna Mutis, PhD^{1*}, Nizar J. Bahlis, MD⁷, Jordan Schechter^{8*}, Christopher Chiu² and **Hervé Avet-Loiseau, MD, PhD**^{9*}

¹Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

²Janssen Research & Development, LLC, Spring House, PA

³Janssen Research & Development, Beerse, Belgium

⁴Vejle Hospital and University of Southern Denmark, Vejle, Denmark

⁵Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC

⁶Winship Cancer Institute/ Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

⁷Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

⁸Janssen Research & Development, LLC, Raritan, NJ

⁹Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France

3029 – Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified by Causal Machine Learning: Out-of-Cohort and Experimental Validation

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Leon Furchtgott, PhD^{1*}, Arnold Bolomsky, PhD^{2*}, Fred Gruber, PhD^{1*}, Mehmet Kemal Samur, PhD³, Jonathan J. Keats, PhD⁴, Jennifer Yesil, MS^{5*}, Kathrin Stangelberger, MSc^{2*}, **Michel Attal, MD, PhD**⁶, Philippe Moreau^{7*}, **Hervé Avet-Loiseau, MD, PhD**^{8*}, Karl Runge, PhD^{1*}, Diane Wuest, PhD^{1*}, Kelly Rich^{1*}, Iya Khalil, PhD^{1*}, Boris Hayete, PhD^{1*}, Heinz Ludwig, MD⁹, Nikhil Munshi, MD³ and Daniel Auclair, PhD^{5*}

¹GNS Healthcare, Cambridge, MA

²Department of Medicine I, Wilhelminenspital, Wilhelminen Cancer Research Institute, Vienna, Austria

³Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

⁴Translational Genomics Research Institute, Phoenix, AZ

⁵Multiple Myeloma Research Foundation, Norwalk, CT

⁶Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

⁷Department of Hematology, Nantes University Hospital, Nantes, France

⁸IUC–Oncopole, Unite de Genomique du Myelome, Toulouse, France

⁹Wilhelminenspital, Vienna, Austria

2628 – Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment–Naive, Elderly Patients with Acute Myeloid Leukemia

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Courtney D. DiNardo, MD, MSc¹, Daniel A. Pollyea, MD^{2,3}, Brian A Jonas, MD, PhD⁴, Marina Konopleva, MD, PhD⁵, Vinod Pullarkat, MD, MRCP⁶, Andrew Wei, MBBS, PhD, FRACP, FRCPA⁷, Hagop M. Kantarjian, MD⁸, Arnaud Pigneux, MD, PhD^{9*}, **Christian Recher, MD, PhD¹⁰**, John F Seymour, MB BS PhD FRACP¹¹, Martin Dunbar, DRPH, MS^{12*}, Tu Xu, PhD^{13*}, Mack Mabry, MD¹², Jalaja Potluri, MD¹², Keith Pratz, MD¹⁴ and Anthony Letai, MD, PhD¹⁵

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

²University of Colorado School of Medicine, Aurora, CO

³Division of Hematology, University of Colorado Denver, Aurora, CO

⁴University of California Davis Comprehensive Cancer Center, Sacramento, CA

⁵MD Anderson Cancer Center, University of Texas, Houston, TX

⁶Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte

⁷The Alfred Hospital and Monash University, Melbourne, Australia

⁸University of Texas MD Anderson Cancer Center, Houston, TX

⁹Hematology Department, Centre Hospitalier Universitaire (CHU) de Bordeaux, Universités de Bordeaux, Bordeaux, France

¹⁰Institut Universitaire du Cancer de Toulouse Oncopole, CHU de Toulouse and Université de Toulouse III, Toulouse, France

¹¹Peter MacCallum Cancer Centre, Melbourne, Australia

¹²AbbVie Inc, North Chicago, IL

¹³AbbVie Inc., North Chicago, IL

¹⁴Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

¹⁵Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA

3217 CMV Status Predicts Survival in Refractory/Relapsed Myeloid Patients after a Clofarabine-Based Sequential Regimen: A Retrospective Study on Behalf of the SFGM-TC

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Amandine Le Bourgeois, PhD^{1}, Myriam Labopin, MD, PhD^{2*}, Felipe Suarez, MD, PhD^{3*}, Regis Peffault De Latour, MD, PhD^{4*}, Didier Blaise⁵, Sylvain Chantepie^{6*}, Stephanie Nguyen-Quoc^{7*}, Natacha Maillard, MD^{8*}, Reza Tabrizi, MD^{9*}, Ibrahim Yakoub-Agha¹⁰, Anne Huynh, MD^{11*}, Tony Marchand^{12*}, Karin Bilger^{13*}, Patrice Ceballos, MD^{14*}, Amandine Charbonnier^{15*}, Pascal Turlure, MD^{16*}, Mohamad Mohty, MD, PhD² and Patrice Chevallier, MD^{17*}*

¹Department of hematology, Nantes University Hospital, Nantes, France

²APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France

³Hématologie Adulte, Hôpital Universitaire Necker, Paris, France

⁴Hematology / Transplantation, Hôpital Saint-Louis AP-HP, PARIS Cedex 10, France

⁵Institut Paoli Calmettes, Department of Hematology, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France

⁶CHU, Caen, France

⁷Department of Hematology, Hopital la Pitié-Salpêtrière, Paris, France

⁸CHU Poitiers, Poitiers, France

⁹Hôpital Haut-Leveque C.H.U. de Bordeaux, Pessac, France

¹⁰CHU de Lille, LIRIC, INSERM U995, Lille, France

¹¹CHU Toulouse, Toulouse, France

¹²CHU Rennes, Rennes, France

¹³Department of hematology, CHU Strasbourg, Strasbourg, FRA

¹⁴Departement of hematology, CHU de Montpellier, Montpellier, France

¹⁵CHU Amiens, Amiens, France

¹⁶Hematology department, Hopital Dupuytren, Limoges, France

¹⁷Clinical Hematology, Nantes University Hospital, Nantes, France

4540 – Long-Term Survival of Patients with Chronic Phase Chronic Myeloid Leukemia Who Received Autologous Stem Cell Transplantation and Further Exposed to Tyrosine Kinase Inhibitors. a Study on Behalf of the French Society of Blood and Marrow Transplantation and the French Group of CML

Program: Oral and Poster Abstracts

Session: 731. Clinical Autologous Transplantation: Results: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Mauricette Michallet, MD, PhD¹, Mohamad Sobh^{1*}, Aude Charbonnier, MD^{2*}, Eric Deconinck, MD, PhD^{3*}, Viviane Dubruille, MD^{4*}, Valerie Coiteux, MD^{5*}, Martine Delain, MD^{6*}, **Francoise Huguet, MD^{7*}**, Delphine Rea, MD⁸, Dominique Bron⁹, Nicole Raus, Data Manager^{10*}, Alain Jacques Delmer, MD¹¹, Pascal Lenain, MD^{12*}, Noel Milpied^{13*}, Francois-Xavier Mahon, MD, PhD¹⁴, Franck Emmanuel Nicolini, MD, PhD¹⁵ and Gabriel Etienne, MD, PhD^{16*}

¹Hematology department 1 G, Centre Hospitalier Lyon Sud, Pierre Benite, France

²Hematology department, Institut Paoli Calmettes, Marseille, France

³Service d`Hématologie, Hopital Jean Minjoz, Besancon, FRA

⁴Clinical Hematology, Nantes University Hospital, Nantes, France

⁵Hematology department, CHU de Lille, Lille, France

⁶Hematology department, CHU Tours, Tours, France

⁷Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

⁸Hematology department, Hopital Saint Louis, Paris, FRA

⁹Dpt of Hematology, Institut Jules Bordet, ULB, Brussels, Belgium

¹⁰SFGM-TC, Lyon, France

¹¹Hematology department, Hopital Robert Debre CHU de Reims, Reims, FRA

¹²Hematology department, Centre Henri Becquerel, Rouen, France

¹³Hématologie Clinique et Thérapie cellulaire, CHU Bordeaux, Bordeaux, France

¹⁴Inserm U1035, Bordeaux Segalen University, Bordeaux, France

¹⁵Centre Hospitalier Lyon Sud, Pierre-Bénite, France

¹⁶Hematology Department, Institut Bergonie, Bordeaux, France

522 – The Measurable Residual Disease Status of Acute Myeloid Leukemia in First Complete Remission at Allogeneic Hematopoietic Cell Transplantation Interacts with Conditioning Intensity to Predict Outcome

Program: Oral and Poster Abstracts

Type: Oral

Session: 732. Clinical Allogeneic Transplantation: Results: GVH and GVL

Sunday, December 10, 2017: 5:45 PM

Bldg C, Lvl 2, C211–C213 (Georgia World Congress Center)

Maria Helena H. Gilleece, MD, FRCPATH, MB, BSc, FRCP^{1*}, Myriam Labopin, MD, PhD^{2*}, Ibrahim Yakoub-Agha³, Liisa Volin⁴, Gerard Socie, MD, PhD⁵, Per Ljungman⁶, **Anne Huynh, MD^{7*}**, Eric Deconinck, MD, PhD^{8*}, Depei Wu, MD⁹, Jean-Henri Bourhis¹⁰, Mohamad Mohty, MD, PhD¹¹, Jean-Yves Cahn¹², Emmanuelle Polge^{13*}, Audrey Mailhol, MSc^{14*}, Bipin N. Savani, MD¹⁵ and Arnon Nagler, MD¹⁶

¹Department of Haematology, St. James Inst. of Onc., Leeds, United Kingdom

²Acute Leukemia Working Party of EBMT, Paris, France

³CHU de Lille, LIRIC, INSERM U995, Lille, France

⁴Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, FIN

⁵Dept. of Hematology – BMT, Hopital St. Louis, Paris, France

⁶Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

⁷Institut Universitaire du Cancer Toulouse, Toulouse, FRA

⁸Service d`Hématologie, Hopital Jean Minjot, Besancon, FRA

⁹Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

¹⁰Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France

¹¹Department of Hematology, Centre de Recherche Saint Antoine, Inserm UMR 938, Sorbonne Université Pierre et Marie Curie, Paris, France

¹²Department of Hematology, CHU Grenoble Alpes, Grenoble, FRA

¹³Paris Study Office/European Center for Biostatistical and Epidemiological Evaluation in Hematopoietic Cell Therapy, Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation, Paris, France

¹⁴Hôpital Saint Antoine, EBMT Paris Study Office / CEREST-TC, Paris, France

¹⁵Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Brentwood, TN

¹⁶Chaim Sheba Medical center, Tel-Hashomer, Israel

3242 – Comparison of Outcome after Allogeneic Stem Cell Transplantation in AML Patients in First or Second Complete Remission Following Either Fludarabin/Busulfan, Flamsa–TBI or Flamsa–Bu Conditioning

Program: Oral and Poster Abstracts

Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Thomas Heinicke, MD^{1*}, Myriam Labopin, MD^{2*}, Christoph Schmid^{3*}, Didier Blaise⁴, Arne Brecht, MD^{5*}, Jean Yves Cahn, MD, PhD^{6*}, Yosr Hicheri^{7*}, **Anne Huynh, MD^{8*}**, Bruno Lioure, MD^{9*}, Noel Milpied^{10*}, Ghulam J Mufti, DM, FRCP, FRCPath^{11*}, Christof Scheid, MD¹², Gérard Socié, MD, PhD¹³, Bipin N. Savani, MD¹⁴ and Arnon Nagler, MD^{15,16,17}

¹Department of Hematology and Oncology, Otto-von-Guericke University, Magdeburg, Germany

²Department of Hematology and Cell Therapy and ALWP EBMT Office, Hospital Saint Antoine Paris, Paris, France

³Klinikum Augsburg, Augsburg, Germany

⁴Institut Paoli Calmettes, Department of Hematology, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France

⁵KMT– Abteilung, DKD Helios–Klinikum, Wiesbaden, Germany

⁶Clinical Hematology, Grenoble University Hospital, Grenoble, France

⁷University Hospital, Montpellier, France

⁸University of Toulouse, Toulouse, France

⁹Nouvel Hopital Civil, Strasbourg, France

¹⁰CHU Bordeaux, Hôpital Haut–leveque, Bordeaux, France

¹¹Haematology Department, King's College London, London, United Kingdom

¹²Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany

¹³Hopital Saint–Louis, Paris, France

¹⁴Department of Medicine, Division of Hematology–Oncology, Vanderbilt University Medical Center, Brentwood, TN

¹⁵Hematology Division and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel–Hashomer, Tel–Aviv, Israel

¹⁶Tel Aviv University, Tel Aviv, Israel

¹⁷Acute Leukemia Working Party of the EBMT, Paris, France

1514 – Systemic ALK–Positive Anaplastic Large–Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

Program: Oral and Poster Abstracts

Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

David Sibon, MD, PhD^{1*}, Dinh–Phong Nguyen, MD^{2*}, Norbert Schmitz, MD^{3*}, Ritsuro Suzuki, MD, PhD⁴, Andrew L Feldman, MD⁵, Remy Gressin, MD^{6*}, **Laurence Lamant, MD, PhD^{7*}**, Dennis D. Weisenburger, MD⁸, Shigeo Nakamura, MD, PhD⁹, Marita Ziepert, PhD^{10*}, Matthew J Maurer, MS¹¹, Martin Bast^{12*}, James O. Armitage, MD¹³, Julie M. Vose, MD, MBA¹³, Herve Tilly¹⁴, Jean–Philippe Jais, MD, PhD^{2*} and Kerry J Savage, MD¹⁵

¹Hematology Department, Necker University Hospital, Paris, France

²Biostatistics Department, Imagine Institute, Paris, France

³ASKLEPIOS Klinik St. Georg, Hamburg, Germany

⁴Department of Oncology & Hematology, Shimane University Hospital, Izumo, Japan

⁵Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

⁶Hematology Department, CHU Grenoble, Grenoble, France

⁷Pathology Department, Institut Universitaire du Cancer – Oncopole, Purpan University Hospital, Toulouse, France

⁸City of Hope, Duarte, CA

⁹Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan

¹⁰Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany

¹¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN

¹²University of Nebraska, Omaha, NE

¹³University of Nebraska Medical Center, Omaha, NE

¹⁴Hematology Department, Centre Henri Becquerel, Rouen, France

¹⁵Division of Medical Oncology and Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada

4028 – Mast Cell Density and Its Clinical Relevance in Waldenstrom's Macroglobulinemia

Program: Oral and Poster Abstracts

Session: 622. Lymphoma Biology—Non-Genetic Studies: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Richard Lemal, MD^{1,2*}, Stephanie Poulain, MD, PhD^{3*}, Albane Ledoux Pilon, MD^{4*}, Lauren Veronese, MD, PhD^{5,6*}, Andrei Tchirkov, MD, PhD^{5,6*}, Benjamin Lebecque^{1,7*}, Jacques-Olivier Bay, MD, PhD^{1,8}, Frederic Charlotte, MD^{9*}, Marc G. Berger, MD, PhD^{10*}, Catherine Godfraind, MD, PhD^{4*}, Loic Ysebaert, MD, PhD^{11*}, Frederic Davi^{12*}, Veronique Leblond¹³, Olivier Hermine, MD, PhD^{14,15*}, Romain Guieze, MD, PhD^{1,16*}, Franck Pages, MD, PhD^{17*} and Olivier Tournilhac, MD, PhD^{18*}

¹University of Auvergne, EA7453, CIC501, Clermont-Ferrand, France

²University Hospital of Clermont-Ferrand, Unit of adult cell therapy and clinical hematology, Clermont-Ferrand, France

³Service d'Hématologie Cellulaire, Centre de Biologie et Pathologie, CHRU de Lille, France/ INSERM UMR-S 1172, IRCL, Lille, FRA

⁴University Hospital of Clermont-Ferrand, Pathology Laboratory, Clermont-Ferrand, France

⁵University Hospital of Clermont-Ferrand, Cytogenetic Laboratory, Clermont-Ferrand, France

⁶University of Auvergne, INSERM UMR 1240, Clermont-Ferrand, France

⁷University Hospital of Clermont-Ferrand, Unit of adult cell therapy and clinical hematology, Clermont-Ferrand, France

⁸Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU, Université d'Auvergne, EA7453, CIC501, Clermont-Ferrand, FRA

⁹AP-HP Hôpital Pitié-Salpêtrière, PARIS, FRA

¹⁰Service d'Hématologie Biologique and EA 7453 CHELTER, CHU Estaing and Université Clermont Auvergne, Clermont-Ferrand, France

¹¹Département d'Hématologie, IUCT-Oncopole, Toulouse, France

¹²Hopital Pitie-Salpetriere and University Pierre et Marie Curie, Paris, France

¹³AP-HP Hôpital Pitié-Salpêtrière, Paris, France

¹⁴Hematology Department, AP-HP Hôpital Necker, University Paris Descartes, Paris, France

¹⁵INSERM UMR 1163 & CNRS URL 8254, Imagine Institute, Paris, France

¹⁶Clinical Hematology, University Hospital of Clermont-Ferrand, Unit of adult cell therapy and clinical hematology, Clermont Ferrand, France

¹⁷Immunomonitoring platform, Hôpital Européen Georges Pompidou, AP-HP, Paris Descartes University, Paris, France

¹⁸Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU, Université Clermont Auvergne, EA7453 CHELTER, CIC501, Clermont Ferrand, France

2624 – Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial

Program: Oral and Poster Abstracts

Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Mohamad Mohty, MD, PhD^{1,2}, Florent Malard, MD, PhD^{1,3*}, Evelyne D'Incan, MD^{4*}, Xavier Thomas, MD⁵, **Christian Recher, MD, PhD⁶**, Anne-Sophie Michallet, MD, PhD^{7*}, Pierre Peterlin, MD^{8*}, Anne Vekhoff^{9*}, Norbert Vey¹⁰, Emilie Plantamura^{11*}, Philippe Lehert^{11*}, Joel Doré^{12*} and Ollivier Legrand, MD, PhD^{9*}

¹Centre de Recherche Saint-Antoine Inserm U938, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France

²Service d'Hématologie Clinique et Thérapie Cellulaire, Hopital Saint Antoine, Paris, France

³Service d'Hématologie Clinique et Thérapie Cellulaire, AP-HP, Hôpital Saint-Antoine, Paris, France

⁴Institut Paoli-Calmette, Marseilles, France

⁵Lyon-Sud University Hospital, Pierre Bénite, France

⁶Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole – CHU de Toulouse, Toulouse, France

⁷Centre Léon Bérard, LYON, FRA

⁸Clinical Hematology, Nantes University Hospital, Nantes, France

⁹APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France

¹⁰Onco-Hematology Department, Paoli-Calmette Cancer Institute, Marseille, France

¹¹MaaT Pharma, Lyon, France

¹²French National Institute for Agricultural Reserch, Jouy-en-Josas, France

1773 – Clonality Analysis Reveals the Order of Acquisition of Copy Number Alterations in Multiple Myeloma

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Anil Aktas Samur, PhD^{1*}, Mehmet Kemal Samur, PhD², Stephane Minvielle^{3*}, Florence Magrangeas^{3*}, Yu-Tzu Tai, PhD⁴, Mariateresa Fulciniti, PhD², Paul G Richardson, MD⁵, Philippe Moreau^{6*}, Kenneth C. Anderson, MD⁷, **Michel Attal, MD, PhD⁸**, **Hervé Avet-Loiseau^{9*}** and Nikhil Munshi, MD²

¹Dana Farber Cancer Institute and Harvard School of Public Health, Boston, MA

²Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

³Université de Nantes, Nantes, France

⁴The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Dana-Farber Cancer Inst., Boston, MA

⁵Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

⁶Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France

⁷Dana-Farber Cancer Institute, Harvard Medical School, Boston

⁸Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

⁹Unit for Genomics in Myeloma, Institut Universitaire du Cancer, Toulouse, France

1335 – Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Program: Oral and Poster Abstracts

Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Pedro H Prata, MD¹, Cecile Bally^{1*}, Thomas Prebet, MD, PhD², **Christian Recher, MD, PhD³**, Geoffroy Venton^{4*}, Xavier Thomas, MD⁵, Emmanuel Raffoux, MD^{1*}, Arnaud Pigneux, MD, PhD^{6*}, Thomas Cluzeau, MD, PhD⁷, Judith Desoutter^{8*}, Julie Gay^{9*}, Claude Preudhomme, PharmD, PhD¹⁰, Pierre Fenaux, MD, PhD¹¹ and Lionel Ades, MD, PhD^{1*}

¹Hématologie Clinique, Hôpital Saint Louis, Paris, France

²Yale Cancer Center, New Haven, CT

³Clinical Hematology, IUCT Oncopole, Toulouse University Hospital, Toulouse, France

⁴Paoli-Calmettes Institute, Marseille, France

⁵Lyon-Sud University Hospital, Pierre Bénite, France

⁶Hematology Department, Centre Hospitalier Universitaire (CHU) de Bordeaux, Universités de Bordeaux, Bordeaux, France

⁷CHU de Nice, Nice, France

⁸Laboratoire d'Hématologie, CHRU Lille, Université de Lille, Lille, FRA

⁹Service d'Hématologie, Centre Hospitalier de la Côte Basque, Bayonne, France

¹⁰Centre de Biologie-Pathologie, Centre Hospitalier Universitaire de Lille, Lille, France

¹¹Hopital Saint-Louis, Paris, France

2901 – Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Program: Oral and Poster Abstracts

Session: 632. Chronic Myeloid Leukemia: Therapy: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Franck Emmanuel Nicolini, MD, PhD^{1,2,3}, Delphine Rea, MD³, Vincent Alcazer, MD^{1*}, **Francoise Huguet, MD^{3,4*}**, Laurence Legros, MD, PhD^{3,5*}, Gaëlle Fossard, MD^{1*}, Elodie Grockowiak, PhD^{6*}, Stéphane Morisset, Stat^{1*}, Pierre Sujobert, MD, PhD^{7*}, Mohamad Sobh^{2*}, Mauricette Michallet, MD, PhD², François Parant, PharmD^{8*} and Marie-Claude Gagnieu, PharmD^{8*}

¹Hematology department, Centre Leon Berard, Lyon, France

²Hematology department 1 G, Centre Hospitalier Lyon Sud, Pierre Benite, France

³Fi-LMC group, Pessac, France

⁴Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

⁵Hematology department, Centre Hospitalier Universitaire de Nice, Nice, France

⁶University of Lyon 1, Lyon, France

⁷Laboratory of Hematology, Centre Hospitalier Lyon Sud, Pierre Benite, France

⁸Laboratory of Pharmacology, Centre Hospitalier Lyon Sud, Pierre Benite, France

156 – Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the AcSé Phase II Trial

Program: Oral and Poster Abstracts

Type: Oral

Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma, New Therapies

Saturday, December 9, 2017: 1:15 PM

Bldg A, Lvl 4, A411–A412 (Georgia World Congress Center)

Xavier Troussard, MD¹, Laure Montané^{2*}, Mourad Tiab^{3*}, Carine Chaletteix, MD^{4*}, Isabelle Grulois^{5*}, Clothilde Lindet^{6*}, Delphine Legoupil^{7*}, Frederic Kohser^{8*}, Diane Pannier^{9*}, Frederic Maloysel, MD, PhD^{10*}, **Pierre Bories^{11*}**, Céline AIT Oukhatar^{12*}, Natalie Hoog Labouret^{13*} and Jean-Yves Blay, MD, PhD^{14*}

¹Department of Haematology, C.H.U. de Caen, Caen Cedex9, France

²Centre Léon Bérard, LYON, France

³University Hospital, La Roche-sur-Yon, France
⁴CHU clermont ferrand, Clermont Ferrand, France
⁵Centre Hospitalier, Saint Malo, France
⁶Hopital Saint Eloi, Montpellier, France
⁷Hopital Morvan – CHU, Brest, France
⁸Hopitaux civils, COLMAR, France
⁹Centre Oscar Lambret, Lille, France
¹⁰Strasbourg Oncologie libérale, STRASBOURG CEDEX, FRA
¹¹Institut Claudius Regaud, Toulouse, France
¹²Unicancer, PARIS, France
¹³Inca, Boulogne Billancourt, France
¹⁴Centre Leon Berard, Lyon, FRA

4368 – The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Program: Oral and Poster Abstracts

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Davine Hofste Op Bruinink, MD^{1*}, Vincent van der Velden, PhD^{2*}, Mark van Duin, PhD^{1*}, Berna Beverloo, PhD^{3*}, Jeroen te Marvelde, BSc^{2*}, Chelsea den Hollander, BSc^{1*}, Rowan Kuiper, MSc^{4*}, Michel Delforge, MD PhD⁵, Martin H van Vliet, PhD^{4*}, Niels WCJ van de Donk, MD PhD⁶, **Hervé Avet-Loiseau, MD PhD^{7*}**, Philippe Moreau^{8*} and Pieter Sonneveld, MD, PhD¹

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

²Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands

³Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands

⁴SkylineDx, Rotterdam, Netherlands

⁵Department of Hematology, LKI–Leuven Cancer Institute, Leuven, Belgium

⁶Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

⁷Unité de Génomique du Myélome, IUC–Oncopole, Toulouse, France

⁸Hôpital Hotel Dieu Et Hme, Nantes, France

4278 – Predicting Mechanisms of Ibrutinib–Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational–Based Modeling for Personalized Therapy with Clinical Validation

Program: Oral and Poster Abstracts

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III

Monday, December 11, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Leylah M. Drusbosky, PhD¹, Aneel Paulus, MD², Anne Quillet Mary, PhD^{3*}, **Loic Ysebaert, MD, PhD^{3*}**, Ansu Kumar, MS^{4*}, Neeraj Kumar Singh, B.Tech^{4*}, Yashaswini Ullal, BE^{4*}, Priyanka Bhargav, BE^{4*}, Humera Azam, MS^{4*}, Taher Abbasi, MS, MBA^{5*}, Shireen Vali, PhD^{5*}, Asher A. Chanan-Khan, MD² and Christopher R. Cogle, MD⁶

¹Department of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL

²Division of Hematology–Oncology, Mayo Clinic, Jacksonville, FL

³Service d'Hematologie, IUCT–Oncopole, Toulouse, France

⁴Cellworks Research India Pvt. Ltd, Bangalore, India

⁵Cellworks Group Inc., San Jose, CA

⁶University of Florida, Gainesville, FL

1502 – Whimsical (Waldenström's Macroglobulinemia Study Involving CART–wheel): Empowering Patients Internationally to Contribute Patient–Derived Data for Observational Research

Program: Oral and Poster Abstracts

Session: 623. Mantle Cell, Follicular, and Other Indolent B–Cell Lymphoma—Clinical Studies:
Poster I

Saturday, December 9, 2017, 5:30 PM–7:30 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Ibrahim Tohidi–Esfahani, B Med^{1,2*}, Andrew Warden^{3*}, Peter deNardis^{4*}, Elena Malunis^{4*}, Shirley D'Sa, MD, FRCP, FRCPath^{5*}, Marie Jose Kersten, MD, PhD⁶, Maria Lia Palomba, MD⁷, Ruth Spearing, MD^{8,9*}, **Loic Ysebaert, MD, PhD^{10*}**, Sheeba K. Thomas, MD¹¹, Constantine S. Tam, MBBS, MD, FRACP,

FRCPA^{12,13,14}, Clare Scott, MBBS PhD FRACP^{15,16*}, Carl Harrington^{4*} and Judith Trotman, FRACP¹⁷

¹Haematology, Concord Repatriation General Hospital, Concord, Australia

²University of Sydney, Sydney, Australia

³WMOzzies Australian Patient Support Group for Waldenström's Macroglobulinemia, Sydney, Australia

⁴International Waldenström's Macroglobulinemia Foundation, Sarasota, FL

⁵University College Hospital, London, GBR

⁶Department of Hematology, Academic Medical Center, Amsterdam, Netherlands

⁷Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

⁸Canterbury District Health Board, Christchurch, NZL

⁹Christchurch Hospital, Christchurch, NZL

¹⁰Departement d'Hematologie, IUCT–Oncopole, Toulouse, France

¹¹Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX

¹²Haematology, St Vincent's Hospital, Kew, VIC, Australia

¹³University of Melbourne, Melbourne, Australia

¹⁴Peter MacCallum Cancer Centre, Melbourne, Australia

¹⁵Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

¹⁶Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

¹⁷Concord Repatriation General Hospital, Sydney, Australia

2260 – Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide

Program: Oral and Poster Abstracts

Session: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Anoosha Habibi, MD^{1*}, Elena Foïs, MD^{2*}, Giovanna Cannas, MD^{3*}, Jean-Antoine Ribeil, MD^{4*}, **Pierre Cougoul, MD^{5*}**, Emmanuelle Bernit, MD^{6*}, Pablo Bartolucci, MD, PhD^{2*} and Frederic Galacteros, MD PhD^{2*}

¹Hopital Henri Mondor – APHP, Creteil Cedex, FRA

²Henri Mondor Hospital – APHP, Creteil, France

³Edouard Herriot Hospital, Lyon, France

⁴Necker Children's Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France

⁵Oncopole, Toulouse, FRA

⁶Hospital La Timone, Marseille, France

2552 – Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Program: Oral and Poster Abstracts

Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II

Sunday, December 10, 2017, 6:00 PM–8:00 PM

Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Alessandro Rambaldi, MD, Prof^{1,2}, **Françoise Rigal-Huguet, MD^{3*}**, Pavel Zak^{4*}, Paul Cannell, MD⁵, Kun Nie, PhD^{6*}, Zachary F. Zimmerman, MD, PhD⁷ and Max S. Topp, MD⁸

¹Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

²Università Statale di Milano, Milano, Italy

³Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France

⁴Fakultni nemocnice Hradec Králové, Hradec Kralove, CZE

⁵Royal Perth Hospital, Perth, Australia

⁶*Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA*

⁷*Global Development, Amgen Inc., Thousand Oaks, CA*

⁸*Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany*